title,drug,lng,lat,enrollment,status,locations,popuptext
Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Ivermectin,-1.663439,42.805408,24,Recruiting,"Clinica Universidad de Navarra, Pamplona, Navarra, Spain","<b>Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial</b><br /><i>Recruiting, n = 24</i><br />Clinica Universidad de Navarra, Pamplona, Navarra, Spain"
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,Ivermectin,44.3755185,33.3458996,100,Completed,"General Directorate of Medical City, Bagdad, Baghdad, Iraq","<b>Efficacy of Ivermectin as Add on Therapy in COVID19 Patients</b><br /><i>Completed, n = 100</i><br />General Directorate of Medical City, Bagdad, Baghdad, Iraq"
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Ivermectin,-58.4053845,-34.5952261,45,Recruiting,"Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina","<b>Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19</b><br /><i>Recruiting, n = 45</i><br />Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina"
Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Ivermectin,77.2120291,28.527476,50,Recruiting,"Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India","<b>Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study</b><br /><i>Recruiting, n = 50</i><br />Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India"
Efficacy of Ivermectin in COVID-19,Ivermectin,74.3726762,31.54089309999999,100,Recruiting,"Combined Military Hospital Lahore, Lahore, Punjab, Pakistan","<b>Efficacy of Ivermectin in COVID-19</b><br /><i>Recruiting, n = 100</i><br />Combined Military Hospital Lahore, Lahore, Punjab, Pakistan"
Ivermectin and Doxycycine in COVID-19 Treatment,Ivermectin,31.0023174,30.8055576,40,Not yet recruiting,"Sherief Abd-Elsalam, Tanta, Egypt","<b>Ivermectin and Doxycycine in COVID-19 Treatment</b><br /><i>Not yet recruiting, n = 40</i><br />Sherief Abd-Elsalam, Tanta, Egypt"
Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy,Ivermectin,-76.59273619999999,39.2967385,60,Not yet recruiting,"Johns Hopkins Hospital, Baltimore, Maryland, United States","<b>Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy</b><br /><i>Not yet recruiting, n = 60</i><br />Johns Hopkins Hospital, Baltimore, Maryland, United States"
The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,Ivermectin,30.9991409,30.7924391,60,Not yet recruiting,"Tanta University, Tanta, Egypt","<b>The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment</b><br /><i>Not yet recruiting, n = 60</i><br />Tanta University, Tanta, Egypt"
New Antiviral Drugs for Treatment of COVID-19,Ivermectin,31.3589223,31.04099489999999,100,Not yet recruiting,"Mansoura University, Mansoura, Select A State Or Province, Egypt","<b>New Antiviral Drugs for Treatment of COVID-19</b><br /><i>Not yet recruiting, n = 100</i><br />Mansoura University, Mansoura, Select A State Or Province, Egypt"
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Ivermectin,-102.2598747,21.9140456,200,Recruiting,"Jose Manuel Arreola Guerra, Aguascalientes, Mexico","<b>Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection</b><br /><i>Recruiting, n = 200</i><br />Jose Manuel Arreola Guerra, Aguascalientes, Mexico"
Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Ivermectin,-99.133208,19.4326077,30,Recruiting,"Outpatient treatment, Mexico City, Mexico","<b>Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19</b><br /><i>Recruiting, n = 30</i><br />Outpatient treatment, Mexico City, Mexico"
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,Ivermectin,-84.5073963,38.0311683,240,Recruiting,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States","<b>Novel Agents for Treatment of High-risk COVID-19 Positive Patients</b><br /><i>Recruiting, n = 240</i><br />University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States"
A Real-life Experience on Treatment of Patients With COVID 19,Ivermectin,30.9951138,30.80150149999999,120,Not yet recruiting,"Tanta university hospital, Tanta, Egypt","<b>A Real-life Experience on Treatment of Patients With COVID 19</b><br /><i>Not yet recruiting, n = 120</i><br />Tanta university hospital, Tanta, Egypt"
A Trial of Remdesivir in Adults With Severe COVID-19,Remdesivir,116.4231333,39.942654,237,Terminated,"Bin Cao, Beijing, Beijing, China","<b>A Trial of Remdesivir in Adults With Severe COVID-19</b><br /><i>Terminated, n = 237</i><br />Bin Cao, Beijing, Beijing, China"
A Trial of Remdesivir in Adults With Mild and Moderate COVID-19,Remdesivir,114.2868443,30.6668794,308,Suspended,"Jin Yin-tan hospital, Wuhan, Hubei, China","<b>A Trial of Remdesivir in Adults With Mild and Moderate COVID-19</b><br /><i>Suspended, n = 308</i><br />Jin Yin-tan hospital, Wuhan, Hubei, China"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.8441325,33.8520823,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.2688043,37.8642168,6000,"Active, not recruiting","Alta Bates Summit Medical Center, Berkeley, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Alta Bates Summit Medical Center, Berkeley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.3824274,37.59230489999999,6000,"Active, not recruiting","Mills-Peninsula Medical Center, Burlingame, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Mills-Peninsula Medical Center, Burlingame, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.0888289,37.69798249999999,6000,"Active, not recruiting","Eden Medical Center, Castro Valley, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Eden Medical Center, Castro Valley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-118.1288238,33.9191479,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.4323129,34.0723526,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-124.1424555,40.7839616,6000,"Active, not recruiting","St Joseph Hospital Eureka, Fortuna, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />St Joseph Hospital Eureka, Fortuna, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-118.2957816,33.7886375,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-118.293899,34.0984583,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-118.3750021,34.0383728,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-118.5896036,34.1709445,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.6653709,33.5610031,6000,"Active, not recruiting","Mission Hospital Regional Medical Center, Mission Viejo, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Mission Hospital Regional Medical Center, Mission Viejo, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.186026,33.897404,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.0795279,37.3691517,6000,"Active, not recruiting","El Camino Hospital, Mountain View, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />El Camino Hospital, Mountain View, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.9296357,33.624397,6000,"Active, not recruiting","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.2582441,37.8235196,6000,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, Oakland, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, Oakland, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.6086894,34.0324565,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.86362,33.779675,6000,"Active, not recruiting","The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-118.4302294,34.2189257,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.4694322,33.905076,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-121.2495341,38.765635,6000,"Active, not recruiting","Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-121.4694362,38.57139480000001,6000,"Active, not recruiting","Sutter Medical Center Sacramento, Sacramento, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sutter Medical Center Sacramento, Sacramento, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.0951878,32.7913395,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.1251884,32.8297116,6000,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.4385597,37.6587814,6000,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.432128,37.7905249,6000,"Active, not recruiting","California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.4429971,37.7824144,6000,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-121.8002512,37.23980410000001,6000,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.1647052,37.7064867,6000,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-121.9988333,37.3360472,6000,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-118.4796445,34.0307739,6000,"Active, not recruiting","Providence St. Johns Medical Center, Santa Monica, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence St. Johns Medical Center, Santa Monica, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.7510442,38.4952463,6000,"Active, not recruiting","Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.1758669,37.4347593,6000,"Active, not recruiting","Stanford Hospital, Stanford, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Stanford Hospital, Stanford, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-104.8375727,39.7452818,6000,"Active, not recruiting","University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-104.9715971,39.7464498,6000,"Active, not recruiting","SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-104.9715971,39.7464498,6000,"Active, not recruiting","SCL Health St. Joseph Hospital, Denver, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />SCL Health St. Joseph Hospital, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-104.9335815,39.7319823,6000,"Active, not recruiting","Rose Medical Center, Denver, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Rose Medical Center, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-105.086874,39.9699702,6000,"Active, not recruiting","SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-72.93556629999999,41.3044229,6000,"Active, not recruiting","Yale-New Haven Hospital, New Haven, Connecticut, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Yale-New Haven Hospital, New Haven, Connecticut, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-157.9000128,21.3632544,6000,"Active, not recruiting","Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-87.67369,41.8728476,6000,"Active, not recruiting","John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-87.6674637,41.8747917,6000,"Active, not recruiting","Rush University Medical Center, Chicago, Illinois, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Rush University Medical Center, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-87.5987133,41.7886079,6000,"Active, not recruiting","University of Chicago, Chicago, Illinois, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University of Chicago, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-86.1633559,39.7903409,6000,"Active, not recruiting","IU Health Methodist Hospital, Indianapolis, Indiana, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />IU Health Methodist Hospital, Indianapolis, Indiana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-91.547979,41.658974,6000,"Active, not recruiting","University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-90.12031669999999,29.9407282,6000,"Active, not recruiting","Tulane University, New Orleans, Louisiana, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Tulane University, New Orleans, Louisiana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-70.276399,43.6531739,6000,"Active, not recruiting","Maine Medical Center, Portland, Maine, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Maine Medical Center, Portland, Maine, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-77.0347487,39.0147079,6000,"Active, not recruiting","Holy Cross Hospital, Silver Spring, Maryland, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Holy Cross Hospital, Silver Spring, Maryland, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-71.06278259999999,42.3495371,6000,"Active, not recruiting","Tufts Medical Center, Boston, Massachusetts, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Tufts Medical Center, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-71.1074884,42.3361091,6000,"Active, not recruiting","Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-71.1049051,42.3397365,6000,"Active, not recruiting","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-83.72787950000001,42.283286,6000,"Active, not recruiting","The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-83.07581019999999,42.3635022,6000,"Active, not recruiting","Henry Ford Health System, Detroit, Michigan, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Henry Ford Health System, Detroit, Michigan, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-93.2615378,44.9722477,6000,"Active, not recruiting","Hennepin Healthcare, Minneapolis, Minnesota, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hennepin Healthcare, Minneapolis, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-92.46688329999999,44.0226255,6000,"Active, not recruiting","Mayo Clinic, Rochester, Minnesota, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Mayo Clinic, Rochester, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-114.0000297,46.8755594,6000,"Active, not recruiting","Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-72.2729872,43.67536399999999,6000,"Active, not recruiting","Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-74.05648819999999,40.8840343,6000,"Active, not recruiting","Hackensack University Medical Center, Hackensack, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hackensack University Medical Center, Hackensack, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-74.5952861,40.5683581,6000,"Active, not recruiting","Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-74.450131,40.4952121,6000,"Active, not recruiting","Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-74.2125193,40.7100492,6000,"Active, not recruiting","Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-74.1653704,40.9028953,6000,"Active, not recruiting","St. Joseph's University Medical Center, Paterson, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />St. Joseph's University Medical Center, Paterson, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.8463639,40.855993,6000,"Active, not recruiting","Jacobi Medical Center, Bronx, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Jacobi Medical Center, Bronx, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.9064045,40.8674032,6000,"Active, not recruiting","James J. Peters Veterans Administration Medical Center, Bronx, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />James J. Peters Veterans Administration Medical Center, Bronx, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.8166244,40.7003783,6000,"Active, not recruiting","Jamaica Hospital Medical Center, Jamaica, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Jamaica Hospital Medical Center, Jamaica, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.4451577,41.4054443,6000,"Active, not recruiting","Danbury Hospital, Lagrangeville, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Danbury Hospital, Lagrangeville, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.7013309,40.7752276,6000,"Active, not recruiting","North Shore University Hospital, Manhasset, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />North Shore University Hospital, Manhasset, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.70738279999999,40.7543773,6000,"Active, not recruiting","North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.9533616,40.78986949999999,6000,"Active, not recruiting","Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.9533616,40.78986949999999,6000,"Active, not recruiting","Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.9533616,40.78986949999999,6000,"Active, not recruiting","Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.9533616,40.78986949999999,6000,"Active, not recruiting","Icahn School of Medicine at Mount Sinai, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Icahn School of Medicine at Mount Sinai, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.941459,40.8409549,6000,"Active, not recruiting","Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-73.9542869,40.7643076,6000,"Active, not recruiting","New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-78.9371331,36.0058487,6000,"Active, not recruiting","Duke University Medical Center, Durham, North Carolina, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Duke University Medical Center, Durham, North Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-81.6060645,41.5052505,6000,"Active, not recruiting","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.8767439,45.5394714,6000,"Active, not recruiting","Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.6127272,45.5275562,6000,"Active, not recruiting","Providence Portland Medical Center, Portland, Oregon, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence Portland Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.771627,45.5104546,6000,"Active, not recruiting","Providence St. Vincent Medical Center, Portland, Oregon, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence St. Vincent Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.5601232,45.4314461,6000,"Active, not recruiting","Kaiser Sunnyside Medical Center, Portland, Oregon, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaiser Sunnyside Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-75.19388289999999,39.9501477,6000,"Active, not recruiting","Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-75.19388289999999,39.9501477,6000,"Active, not recruiting","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-75.1507582,40.0050435,6000,"Active, not recruiting","Temple University Hospital, Philadelphia, Pennsylvania, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Temple University Hospital, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-71.398257,41.851722,6000,"Active, not recruiting","The Miriam Hospital, Providence, Rhode Island, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The Miriam Hospital, Providence, Rhode Island, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-81.0333789,34.0279493,6000,"Active, not recruiting","Prisma Health Richland Hospital, Columbia, South Carolina, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Prisma Health Richland Hospital, Columbia, South Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-82.4109998,34.818455,6000,"Active, not recruiting","Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-96.82346,32.7608903,6000,"Active, not recruiting","The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-96.8350262,32.8086365,6000,"Active, not recruiting","UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-96.77904799999999,32.7896805,6000,"Active, not recruiting","Baylor University Medical Center, Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Baylor University Medical Center, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-96.8350262,32.8086365,6000,"Active, not recruiting","UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-96.8419366,32.8173287,6000,"Active, not recruiting","UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-97.345412,32.7296877,6000,"Active, not recruiting","Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-95.399568,29.7106626,6000,"Active, not recruiting","Houston Methodist Hospital, Houston, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Houston Methodist Hospital, Houston, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-97.3640532,31.0779405,6000,"Active, not recruiting","Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-111.8366784,40.77157160000001,6000,"Active, not recruiting","University of Utah Health, Salt Lake City, Utah, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University of Utah Health, Salt Lake City, Utah, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-77.127521,38.8891114,6000,"Active, not recruiting","Virginia Hospital Center, Arlington, Virginia, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Virginia Hospital Center, Arlington, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-77.2281251,38.8573966,6000,"Active, not recruiting","Inova Fairfax Medical Campus, Falls Church, Virginia, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Inova Fairfax Medical Campus, Falls Church, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-77.4299508,37.5408047,6000,"Active, not recruiting","VCU Health Medical Center, Richmond, Virginia, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />VCU Health Medical Center, Richmond, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.2052146,48.0000596,6000,"Active, not recruiting","Providence Regional Medical Center Everett, Everett, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence Regional Medical Center Everett, Everett, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-119.2822234,46.2813864,6000,"Active, not recruiting","Kadlec Regional Medical Center, Kennewick, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kadlec Regional Medical Center, Kennewick, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.8479904,47.0529957,6000,"Active, not recruiting","Providence St. Peter Hospital, Olympia, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Providence St. Peter Hospital, Olympia, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.3277093,47.6099974,6000,"Active, not recruiting","Virginia Mason Medical Center, Seattle, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Virginia Mason Medical Center, Seattle, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.32148720000001,47.6063315,6000,"Active, not recruiting","Swedish Center for Comprehensive Care, Seattle, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Swedish Center for Comprehensive Care, Seattle, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-117.4235336,47.6517794,6000,"Active, not recruiting","MultiCare Deaconess Hospital, Spokane, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />MultiCare Deaconess Hospital, Spokane, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.45297360000001,47.2593705,6000,"Active, not recruiting","MultiCare Tacoma General Hospital, Tacoma, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />MultiCare Tacoma General Hospital, Tacoma, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-122.4478581,47.24535830000001,6000,"Active, not recruiting","St Joseph Medical Center, Tacoma, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />St Joseph Medical Center, Tacoma, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,113.261861,23.113169,6000,"Active, not recruiting","The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-0.6043875,44.8274249,6000,"Active, not recruiting","CHU Pellegrin, Bordeaux, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />CHU Pellegrin, Bordeaux, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,3.8623414,43.6301844,6000,"Active, not recruiting","CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-1.5545498,47.2107575,6000,"Active, not recruiting","CHU de Nantes-Hotel Dieu, Nantes, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />CHU de Nantes-Hotel Dieu, Nantes, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,2.3672856,48.8771612,6000,"Active, not recruiting","Hopital Saint-Louis, Paris, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hopital Saint-Louis, Paris, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,2.3827263,48.8488116,6000,"Active, not recruiting","Hopital Saint Antoine, Paris, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hopital Saint Antoine, Paris, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,13.3766245,52.5264618,6000,"Active, not recruiting","Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,6.792286100000001,51.195064,6000,"Active, not recruiting","Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,9.974533,53.59081159999999,6000,"Active, not recruiting","Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,10.1433156,54.3307016,6000,"Active, not recruiting","Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,12.375768,51.385368,6000,"Active, not recruiting","Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,11.599781,48.13797599999999,6000,"Active, not recruiting","Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,11.57756,48.16945,6000,"Active, not recruiting","Klinik für Hämatologie, Onkologie, Immunologie, München, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Klinik für Hämatologie, Onkologie, Immunologie, München, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,9.185813999999999,48.815163,6000,"Active, not recruiting","Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,114.201222,22.378404,6000,"Active, not recruiting","Prince of Wales Hospital, Hong Kong, Hong Kong","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Prince of Wales Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,114.1338324,22.3415435,6000,"Active, not recruiting","Princess Margaret Hospital, Hong Kong, Hong Kong","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Princess Margaret Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,114.1312557,22.2701076,6000,"Active, not recruiting","Queen Mary Hospital, Hong Kong, Hong Kong","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Queen Mary Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,9.638066,45.686107,6000,"Active, not recruiting","UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,10.233707,45.5614101,6000,"Active, not recruiting","ASST degli Spedali Civili di Brescia, Brescia, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />ASST degli Spedali Civili di Brescia, Brescia, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,10.0523058,45.1300126,6000,"Active, not recruiting","ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,9.229135099999999,45.4991785,6000,"Active, not recruiting","UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,9.1230078,45.5192174,6000,"Active, not recruiting","Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,9.197922,45.45888679999999,6000,"Active, not recruiting","UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,11.8880771,45.4015071,6000,"Active, not recruiting","UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,10.3083481,44.8016341,6000,"Active, not recruiting","Azienda Ospedaliero Universitaria di Parma, Parma, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Azienda Ospedaliero Universitaria di Parma, Parma, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,9.1488319,45.1962179,6000,"Active, not recruiting","UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,9.680999,45.05516129999999,6000,"Active, not recruiting","Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,12.4564793,41.866501,6000,"Active, not recruiting","UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,7.659655399999998,45.0889028,6000,"Active, not recruiting","Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,139.604878,35.4688457,6000,"Active, not recruiting","Yokohama Municipal Citizen's Hospital, Kanagawa, Japan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Yokohama Municipal Citizen's Hospital, Kanagawa, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,136.9436445,35.1738983,6000,"Active, not recruiting","Nagoya City East Medical Center, Nagoya, Japan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Nagoya City East Medical Center, Nagoya, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,139.818798,35.6946101,6000,"Active, not recruiting","Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,128.6051356,35.865942,6000,"Active, not recruiting","Kyungpook National University Hospital, Daegu, Korea, Republic of","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kyungpook National University Hospital, Daegu, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,127.0981666,37.6127725,6000,"Active, not recruiting","Seoul Medical Center, Seoul, Korea, Republic of","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Seoul Medical Center, Seoul, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,127.0056589,37.5672412,6000,"Active, not recruiting","National Medical Center, Seoul, Korea, Republic of","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />National Medical Center, Seoul, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,4.959209599999999,52.2938961,6000,"Active, not recruiting","Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,4.4785036,52.1660315,6000,"Active, not recruiting","Leiden University Medical Center, Leiden, Netherlands","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Leiden University Medical Center, Leiden, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,4.467854099999999,51.9108848,6000,"Active, not recruiting","Erasmus Medical Centre, Rotterdam, Netherlands","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Erasmus Medical Centre, Rotterdam, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,103.7831756,1.2937278,6000,"Active, not recruiting","National University Hospital, Singapore, Singapore","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />National University Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,103.8348123,1.2804242,6000,"Active, not recruiting","Singapore General Hospital, Singapore, Singapore","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Singapore General Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,103.8472413,1.3221188,6000,"Active, not recruiting","National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-3.3475567,40.5093672,6000,"Active, not recruiting","Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-8.3879435,43.3444418,6000,"Active, not recruiting","Complejo Hospitalario Universitario A Coruña, A Coruña, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Complejo Hospitalario Universitario A Coruña, A Coruña, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,2.142488,41.4283018,6000,"Active, not recruiting","Hospital Universitari Vall d'Hebron, Barcelona, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitari Vall d'Hebron, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,2.1042573,41.3448959,6000,"Active, not recruiting","Hospital Universitari de Bellvitge, Barcelona, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitari de Bellvitge, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,2.1523119,41.3894436,6000,"Active, not recruiting","Hospital Clinic de Barcelona, Barcelona, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Clinic de Barcelona, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-2.983914,43.2820309,6000,"Active, not recruiting","Hospital Universitario Cruces, Bizkaia, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario Cruces, Bizkaia, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-3.6951156,40.48760430000001,6000,"Active, not recruiting","Hospital Universitario Ramón y Cajal, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario Ramón y Cajal, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-3.7190495,40.43899529999999,6000,"Active, not recruiting","Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-3.6990068,40.3760381,6000,"Active, not recruiting","Hospital Universitario 12 de Octubre, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario 12 de Octubre, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-3.6873977,40.4811633,6000,"Active, not recruiting","Hospital Universitario La Paz, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario La Paz, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-4.4498416,36.7231736,6000,"Active, not recruiting","Hospital Regional Universitario de Málaga, Málaga, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Regional Universitario de Málaga, Málaga, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-5.9803696,37.3618418,6000,"Active, not recruiting","Hospital Universitario Virgen del Rocio, Sevilla, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hospital Universitario Virgen del Rocio, Sevilla, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,11.9614318,57.68236719999999,6000,"Active, not recruiting","Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,13.0016352,55.589568,6000,"Active, not recruiting","SUS (Skanes University Hospital), Malmo, Sweden","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />SUS (Skanes University Hospital), Malmo, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,18.030376,59.3482904,6000,"Active, not recruiting","Karolinska University Hospital, Stockholm, Sweden","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Karolinska University Hospital, Stockholm, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,6.1490487,46.19331469999999,6000,"Active, not recruiting","Hopitaux Universitaires de Genève, Genève 14, Switzerland","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hopitaux Universitaires de Genève, Genève 14, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,8.7908616,46.1688293,6000,"Active, not recruiting","Ospedale Regionale di Locarno La Carità, Lugano, Switzerland","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Ospedale Regionale di Locarno La Carità, Lugano, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,8.549177499999999,47.3766158,6000,"Active, not recruiting","Universitätsspital Zürich, Zürich, Switzerland","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Universitätsspital Zürich, Zürich, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,120.3223407,22.6796829,6000,"Active, not recruiting","Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,120.6804919,24.1572247,6000,"Active, not recruiting","China Medical University Hospital, Taichung, Taiwan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />China Medical University Hospital, Taichung, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,121.5189863,25.0407391,6000,"Active, not recruiting","National Taiwan University Hospital, Taipei City, Taiwan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />National Taiwan University Hospital, Taipei City, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-0.1743487,51.5178108,6000,"Active, not recruiting","Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-3.1357575,55.9215065,6000,"Active, not recruiting","Royal Infirmary of Edinburgh, Edinburgh, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Royal Infirmary of Edinburgh, Edinburgh, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-4.340215199999999,55.8628356,6000,"Active, not recruiting","Queen Elizabeth University Hospital, Glasgow, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Queen Elizabeth University Hospital, Glasgow, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-0.3582799,53.74422029999999,6000,"Active, not recruiting","Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-2.7995125,54.0423015,6000,"Active, not recruiting","Royal Lancaster Hospital, Lancaster, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Royal Lancaster Hospital, Lancaster, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-2.9641248,53.4093831,6000,"Active, not recruiting","Liverpool University Hospital, Liverpool, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Liverpool University Hospital, Liverpool, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-0.3195181,51.57515009999999,6000,"Active, not recruiting","Northwick Park Hospital, London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Northwick Park Hospital, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-0.165596,51.553237,6000,"Active, not recruiting","Royal Free London NHS Foundation Trust, London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Royal Free London NHS Foundation Trust, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-0.0938548,51.4681404,6000,"Active, not recruiting","King's College Hospital NHS Trust, London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />King's College Hospital NHS Trust, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-0.1340401,51.52455920000001,6000,"Active, not recruiting","University College London, London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />University College London, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-2.2277393,53.4607569,6000,"Active, not recruiting","Manchester University NHS Foundation Trust, Manchester, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Manchester University NHS Foundation Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-2.2277393,53.4607569,6000,"Active, not recruiting","Manchester University NHS Foundation Trust, Manchester, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Manchester University NHS Foundation Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-2.2294865,53.5178824,6000,"Active, not recruiting","Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-4.116408,50.4166994,6000,"Active, not recruiting","Derriford Hospital, Plymouth, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Derriford Hospital, Plymouth, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),Remdesivir,-1.4923035,53.379171,6000,"Active, not recruiting","Sheffield Teaching Hospitals, Sheffield, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</b><br /><i>Active, not recruiting, n = 6000</i><br />Sheffield Teaching Hospitals, Sheffield, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.8441325,33.8520823,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.2688043,37.8642168,1600,"Active, not recruiting","Alta Bates Summit Medical Center, Berkeley, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Alta Bates Summit Medical Center, Berkeley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.3824274,37.59230489999999,1600,"Active, not recruiting","Mills-Peninsula Medical Center, Burlingame, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Mills-Peninsula Medical Center, Burlingame, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.0888289,37.69798249999999,1600,"Active, not recruiting","Eden Medical Center, Castro Valley, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Eden Medical Center, Castro Valley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-118.1288238,33.9191479,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.4323129,34.0723526,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-124.1424555,40.7839616,1600,"Active, not recruiting","St Joseph Hospital Eureka, Fortuna, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />St Joseph Hospital Eureka, Fortuna, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-118.2957816,33.7886375,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-118.293899,34.0984583,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-118.3750021,34.0383728,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-118.5896036,34.1709445,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.6653709,33.5610031,1600,"Active, not recruiting","Mission Hospital Regional Medical Center, Mission Viejo, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Mission Hospital Regional Medical Center, Mission Viejo, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.186026,33.897404,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.0795279,37.3691517,1600,"Active, not recruiting","El Camino Hospital, Mountain View, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />El Camino Hospital, Mountain View, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.9296357,33.624397,1600,"Active, not recruiting","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.2582441,37.8235196,1600,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, Oakland, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, Oakland, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.6086894,34.0324565,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.86362,33.779675,1600,"Active, not recruiting","The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-118.4302294,34.2189257,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.4694322,33.905076,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-121.2495341,38.765635,1600,"Active, not recruiting","Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-121.4694362,38.57139480000001,1600,"Active, not recruiting","Sutter Medical Center Sacramento, Sacramento, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sutter Medical Center Sacramento, Sacramento, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.0951878,32.7913395,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.1251884,32.8297116,1600,"Active, not recruiting","Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.4385597,37.6587814,1600,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.432128,37.7905249,1600,"Active, not recruiting","California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.4429971,37.7824144,1600,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-121.8002512,37.23980410000001,1600,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.1647052,37.7064867,1600,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-121.9988333,37.3360472,1600,"Active, not recruiting","Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-118.4796445,34.0307739,1600,"Active, not recruiting","Providence St. Johns Medical Center, Santa Monica, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence St. Johns Medical Center, Santa Monica, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.7510442,38.4952463,1600,"Active, not recruiting","Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.1758669,37.4347593,1600,"Active, not recruiting","Stanford Hospital, Stanford, California, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Stanford Hospital, Stanford, California, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-104.8375727,39.7452818,1600,"Active, not recruiting","University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-104.9715971,39.7464498,1600,"Active, not recruiting","SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-104.9715971,39.7464498,1600,"Active, not recruiting","SCL Health St. Joseph Hospital, Denver, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />SCL Health St. Joseph Hospital, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-104.9335815,39.7319823,1600,"Active, not recruiting","Rose Medical Center, Denver, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Rose Medical Center, Denver, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-105.086874,39.9699702,1600,"Active, not recruiting","SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-72.92234309999999,41.3163244,1600,"Active, not recruiting","Yale University, New Haven, Connecticut, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Yale University, New Haven, Connecticut, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-157.9000128,21.3632544,1600,"Active, not recruiting","Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-87.67369,41.8728476,1600,"Active, not recruiting","Cook County General Hospital, Chicago, Illinois, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Cook County General Hospital, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-87.6674637,41.8747917,1600,"Active, not recruiting","Rush University Medical Center, Chicago, Illinois, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Rush University Medical Center, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-87.5987133,41.7886079,1600,"Active, not recruiting","University of Chicago, Chicago, Illinois, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University of Chicago, Chicago, Illinois, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-86.1633559,39.7903409,1600,"Active, not recruiting","IU Health Methodist Hospital, Indianapolis, Indiana, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />IU Health Methodist Hospital, Indianapolis, Indiana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-91.547979,41.658974,1600,"Active, not recruiting","University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-90.12031669999999,29.9407282,1600,"Active, not recruiting","Tulane University, New Orleans, Louisiana, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Tulane University, New Orleans, Louisiana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-70.276399,43.6531739,1600,"Active, not recruiting","Maine Medical Center, Portland, Maine, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Maine Medical Center, Portland, Maine, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-77.0347487,39.0147079,1600,"Active, not recruiting","Holy Cross Hospital, Silver Spring, Maryland, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Holy Cross Hospital, Silver Spring, Maryland, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-71.06278259999999,42.3495371,1600,"Active, not recruiting","Tufts Medical Center, Boston, Massachusetts, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Tufts Medical Center, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-71.1074884,42.3361091,1600,"Active, not recruiting","Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-71.1049051,42.3397365,1600,"Active, not recruiting","Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-83.72787950000001,42.283286,1600,"Active, not recruiting","The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-83.07581019999999,42.3635022,1600,"Active, not recruiting","Henry Ford Health System, Detroit, Michigan, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Henry Ford Health System, Detroit, Michigan, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-93.2615378,44.9722477,1600,"Active, not recruiting","Hennepin Healthcare, Minneapolis, Minnesota, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hennepin Healthcare, Minneapolis, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-92.46688329999999,44.0226255,1600,"Active, not recruiting","Mayo Clinic, Rochester, Minnesota, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Mayo Clinic, Rochester, Minnesota, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-114.0000297,46.8755594,1600,"Active, not recruiting","Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-72.2729872,43.67536399999999,1600,"Active, not recruiting","Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-74.05648819999999,40.8840343,1600,"Active, not recruiting","Hackensack Medical Center, Hackensack, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hackensack Medical Center, Hackensack, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-74.5952861,40.5683581,1600,"Active, not recruiting","Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-74.450131,40.4952121,1600,"Active, not recruiting","Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-74.2125193,40.7100492,1600,"Active, not recruiting","Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-74.1653704,40.9028953,1600,"Active, not recruiting","St. Joseph's University Medical Center, Paterson, New Jersey, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />St. Joseph's University Medical Center, Paterson, New Jersey, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.8463639,40.855993,1600,"Active, not recruiting","Jacobi Medical Center, Bronx, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Jacobi Medical Center, Bronx, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.9064045,40.8674032,1600,"Active, not recruiting","James J. Peters Veterans Administration Medical Center, Bronx, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />James J. Peters Veterans Administration Medical Center, Bronx, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.8166244,40.7003783,1600,"Active, not recruiting","Jamaica Hospital Medical Center, Jamaica, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Jamaica Hospital Medical Center, Jamaica, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.4451577,41.4054443,1600,"Active, not recruiting","Danbury Hospital, Lagrangeville, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Danbury Hospital, Lagrangeville, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.7013309,40.7752276,1600,"Active, not recruiting","North Shore University Hospital, Manhasset, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />North Shore University Hospital, Manhasset, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.70738279999999,40.7543773,1600,"Active, not recruiting","North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.9533616,40.78986949999999,1600,"Active, not recruiting","Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.9533616,40.78986949999999,1600,"Active, not recruiting","Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.9533616,40.78986949999999,1600,"Active, not recruiting","Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.9533616,40.78986949999999,1600,"Active, not recruiting","Icahn School of Medicine at Mount Sinai, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Icahn School of Medicine at Mount Sinai, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.941459,40.8409549,1600,"Active, not recruiting","Columbia University Irving Medical Center, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Columbia University Irving Medical Center, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-73.9542869,40.7643076,1600,"Active, not recruiting","Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-78.9371331,36.0058487,1600,"Active, not recruiting","Duke University Medical Center, Durham, North Carolina, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Duke University Medical Center, Durham, North Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-81.6060645,41.5052505,1600,"Active, not recruiting","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.8767439,45.5394714,1600,"Active, not recruiting","Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.6127272,45.5275562,1600,"Active, not recruiting","Providence Portland Medical Center, Portland, Oregon, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence Portland Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.771627,45.5104546,1600,"Active, not recruiting","Providence St. Vincent Medical Center, Portland, Oregon, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence St. Vincent Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.5601232,45.4314461,1600,"Active, not recruiting","Kaiser Sunnyside Medical Center, Portland, Oregon, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaiser Sunnyside Medical Center, Portland, Oregon, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-75.19388289999999,39.9501477,1600,"Active, not recruiting","Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-75.19388289999999,39.9501477,1600,"Active, not recruiting","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-75.1507582,40.0050435,1600,"Active, not recruiting","Temple University Hospital, Philadelphia, Pennsylvania, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Temple University Hospital, Philadelphia, Pennsylvania, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-71.398257,41.851722,1600,"Active, not recruiting","The Miriam Hospital, Providence, Rhode Island, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The Miriam Hospital, Providence, Rhode Island, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-81.0333789,34.0279493,1600,"Active, not recruiting","Prisma Health Richland Hospital, Columbia, South Carolina, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Prisma Health Richland Hospital, Columbia, South Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-82.4109998,34.818455,1600,"Active, not recruiting","Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-96.82346,32.7608903,1600,"Active, not recruiting","The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-96.8350262,32.8086365,1600,"Active, not recruiting","UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-96.77904799999999,32.7896805,1600,"Active, not recruiting","Baylor University Medical Center, Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Baylor University Medical Center, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-96.8350262,32.8086365,1600,"Active, not recruiting","UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-96.8419366,32.8173287,1600,"Active, not recruiting","UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-97.345412,32.7296877,1600,"Active, not recruiting","Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-95.399568,29.7106626,1600,"Active, not recruiting","Houston Methodist Hospital, Houston, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Houston Methodist Hospital, Houston, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-97.3640532,31.0779405,1600,"Active, not recruiting","Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-111.8366784,40.77157160000001,1600,"Active, not recruiting","University of Utah Health, Salt Lake City, Utah, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University of Utah Health, Salt Lake City, Utah, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-77.127521,38.8891114,1600,"Active, not recruiting","Virginia Hospital Center, Arlington, Virginia, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Virginia Hospital Center, Arlington, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-77.2281251,38.8573966,1600,"Active, not recruiting","Inova Fairfax Hospital, Falls Church, Virginia, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Inova Fairfax Hospital, Falls Church, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-77.4299508,37.5408047,1600,"Active, not recruiting","VCU Health Medical Center, Richmond, Virginia, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />VCU Health Medical Center, Richmond, Virginia, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.2052146,48.0000596,1600,"Active, not recruiting","Providence Medical Research Center, Everett, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence Medical Research Center, Everett, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-119.2822234,46.2813864,1600,"Active, not recruiting","Kadlec Regional Medical Center, Kennewick, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kadlec Regional Medical Center, Kennewick, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.8479904,47.0529957,1600,"Active, not recruiting","Providence St. Peter Hospital, Olympia, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Providence St. Peter Hospital, Olympia, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.3277093,47.6099974,1600,"Active, not recruiting","Virginia Mason Medical Center, Seattle, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Virginia Mason Medical Center, Seattle, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.32148720000001,47.6063315,1600,"Active, not recruiting","Swedish Center for Comprehensive Care, Seattle, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Swedish Center for Comprehensive Care, Seattle, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-117.4235336,47.6517794,1600,"Active, not recruiting","MultiCare Deaconess Hospital, Spokane, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />MultiCare Deaconess Hospital, Spokane, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.45297360000001,47.2593705,1600,"Active, not recruiting","MultiCare Tacoma General Hospital, Tacoma, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />MultiCare Tacoma General Hospital, Tacoma, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-122.4478581,47.24535830000001,1600,"Active, not recruiting","St Joseph Medical Center, Tacoma, Washington, United States","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />St Joseph Medical Center, Tacoma, Washington, United States"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,113.261861,23.113169,1600,"Active, not recruiting","The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-0.6043875,44.8274249,1600,"Active, not recruiting","CHU Pellegrin, Bordeaux, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />CHU Pellegrin, Bordeaux, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,3.8623414,43.6301844,1600,"Active, not recruiting","CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-1.5545498,47.2107575,1600,"Active, not recruiting","CHU de Nantes-Hotel Dieu, Nantes, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />CHU de Nantes-Hotel Dieu, Nantes, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,2.3672856,48.8771612,1600,"Active, not recruiting","Hopital Saint-Louis, Paris, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hopital Saint-Louis, Paris, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,2.3827263,48.8488116,1600,"Active, not recruiting","Hopital Saint Antoine, Paris, France","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hopital Saint Antoine, Paris, France"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,13.3766245,52.5264618,1600,"Active, not recruiting","Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,6.792286100000001,51.195064,1600,"Active, not recruiting","Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,9.974533,53.59081159999999,1600,"Active, not recruiting","Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,10.1433156,54.3307016,1600,"Active, not recruiting","Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,12.375768,51.385368,1600,"Active, not recruiting","Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,11.599781,48.13797599999999,1600,"Active, not recruiting","Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,11.57756,48.16945,1600,"Active, not recruiting","Klinik für Hämatologie, Onkologie, Immunologie, München, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Klinik für Hämatologie, Onkologie, Immunologie, München, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,9.185813999999999,48.815163,1600,"Active, not recruiting","Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,114.201222,22.378404,1600,"Active, not recruiting","Prince of Wales Hospital, Hong Kong, Hong Kong","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Prince of Wales Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,114.1338324,22.3415435,1600,"Active, not recruiting","Princess Margaret Hospital, Hong Kong, Hong Kong","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Princess Margaret Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,114.1312557,22.2701076,1600,"Active, not recruiting","Queen Mary Hospital, Hong Kong, Hong Kong","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Queen Mary Hospital, Hong Kong, Hong Kong"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,9.638066,45.686107,1600,"Active, not recruiting","UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,10.233707,45.5614101,1600,"Active, not recruiting","ASST degli Spedali Civili di Brescia, Brescia, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />ASST degli Spedali Civili di Brescia, Brescia, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,10.0523058,45.1300126,1600,"Active, not recruiting","ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,9.229135099999999,45.4991785,1600,"Active, not recruiting","UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,9.2190716,45.4847912,1600,"Active, not recruiting","ASST Fatebenefratelli Sacco, Milano, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />ASST Fatebenefratelli Sacco, Milano, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,9.197922,45.45888679999999,1600,"Active, not recruiting","UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,11.8909972,45.4042074,1600,"Active, not recruiting","UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,10.3083481,44.8016341,1600,"Active, not recruiting","Azienda Ospedaliero Universitaria di Parma, Parma, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Azienda Ospedaliero Universitaria di Parma, Parma, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,9.1449014,45.2006198,1600,"Active, not recruiting","Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,9.680999,45.05516129999999,1600,"Active, not recruiting","Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,12.4564793,41.866501,1600,"Active, not recruiting","UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,7.659655399999998,45.0889028,1600,"Active, not recruiting","Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,139.604878,35.4688457,1600,"Active, not recruiting","Yokohama Municipal Citizen's Hospital, Kanagawa, Japan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Yokohama Municipal Citizen's Hospital, Kanagawa, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,136.9436445,35.1738983,1600,"Active, not recruiting","Nagoya City East Medical Center, Nagoya, Japan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Nagoya City East Medical Center, Nagoya, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,139.818798,35.6946101,1600,"Active, not recruiting","Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,128.6051356,35.865942,1600,"Active, not recruiting","Kyungpook National University Hospital, Daegu, Korea, Republic of","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kyungpook National University Hospital, Daegu, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,127.0981666,37.6127725,1600,"Active, not recruiting","Seoul Medical Center, Seoul, Korea, Republic of","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Seoul Medical Center, Seoul, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,127.0056589,37.5672412,1600,"Active, not recruiting","National Medical Center, Seoul, Korea, Republic of","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />National Medical Center, Seoul, Korea, Republic of"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,4.959209599999999,52.2938961,1600,"Active, not recruiting","Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,4.4785036,52.1660315,1600,"Active, not recruiting","Leiden University Medical Center, Leiden, Netherlands","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Leiden University Medical Center, Leiden, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,4.467854099999999,51.9108848,1600,"Active, not recruiting","Erasmus Medical Centre, Rotterdam, Netherlands","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Erasmus Medical Centre, Rotterdam, Netherlands"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,103.7831756,1.2937278,1600,"Active, not recruiting","National University Hospital, Singapore, Singapore","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />National University Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,103.8348123,1.2804242,1600,"Active, not recruiting","Singapore General Hospital, Singapore, Singapore","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Singapore General Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,103.8472413,1.3221188,1600,"Active, not recruiting","National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-3.3475567,40.5093672,1600,"Active, not recruiting","Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-8.3879435,43.3444418,1600,"Active, not recruiting","Complejo Hospitalario Universitario A Coruña, A Coruña, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Complejo Hospitalario Universitario A Coruña, A Coruña, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,2.142488,41.4283018,1600,"Active, not recruiting","Hospital Universitario Vall d'Hebron, Barcelona, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Vall d'Hebron, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,2.1042573,41.3448959,1600,"Active, not recruiting","Hospital Universitari de Bellvitge, Barcelona, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitari de Bellvitge, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,2.1523119,41.3894436,1600,"Active, not recruiting","Hospital Clinic de Barcelona, Barcelona, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Clinic de Barcelona, Barcelona, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-2.983914,43.2820309,1600,"Active, not recruiting","Hospital Universitario Cruces, Bizkaia, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Cruces, Bizkaia, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-3.6951156,40.48760430000001,1600,"Active, not recruiting","Hospital Universitario Ramón y Cajal, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Ramón y Cajal, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-3.7190495,40.43899529999999,1600,"Active, not recruiting","Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-3.6990068,40.3760381,1600,"Active, not recruiting","Hospital Universitario 12 de Octubre, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario 12 de Octubre, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-3.6873977,40.4811633,1600,"Active, not recruiting","Hospital Universitario La Paz, Madrid, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario La Paz, Madrid, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-4.4498416,36.7231736,1600,"Active, not recruiting","Hospital Regional Universitario de Málaga, Málaga, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Regional Universitario de Málaga, Málaga, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-5.9803696,37.3618418,1600,"Active, not recruiting","Hospital Universitario Virgen del Rocio, Sevilla, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitario Virgen del Rocio, Sevilla, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-0.3762115,39.44351,1600,"Active, not recruiting","Hospital Universitari i Politecnic La Fe, Valencia, Spain","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hospital Universitari i Politecnic La Fe, Valencia, Spain"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,11.9614318,57.68236719999999,1600,"Active, not recruiting","Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,13.0016352,55.589568,1600,"Active, not recruiting","SUS (Skanes University Hospital), Malmo, Sweden","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />SUS (Skanes University Hospital), Malmo, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,18.030376,59.3482904,1600,"Active, not recruiting","Karolinska University Hospital, Stockholm, Sweden","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Karolinska University Hospital, Stockholm, Sweden"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,6.1490487,46.19331469999999,1600,"Active, not recruiting","Hopitaux Universitaires de Genève, Genève 14, Switzerland","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hopitaux Universitaires de Genève, Genève 14, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,8.7908616,46.1688293,1600,"Active, not recruiting","Ospedale Regionale di Locarno La Carità, Lugano, Switzerland","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Ospedale Regionale di Locarno La Carità, Lugano, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,8.549177499999999,47.3766158,1600,"Active, not recruiting","Universitätsspital Zürich, Zürich, Switzerland","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Universitätsspital Zürich, Zürich, Switzerland"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,120.3223407,22.6796829,1600,"Active, not recruiting","Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,120.6804919,24.1572247,1600,"Active, not recruiting","China Medical University Hospital, Taichung, Taiwan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />China Medical University Hospital, Taichung, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,121.5189863,25.0407391,1600,"Active, not recruiting","National Taiwan University Hospital, Taipei City, Taiwan","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />National Taiwan University Hospital, Taipei City, Taiwan"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-0.1743487,51.5178108,1600,"Active, not recruiting","Imperial College NHS Trust, London, Greater London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Imperial College NHS Trust, London, Greater London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-3.1357575,55.9215065,1600,"Active, not recruiting","NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-4.340215199999999,55.8628356,1600,"Active, not recruiting","Queen Elizabeth University Hospital, Glasgow, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Queen Elizabeth University Hospital, Glasgow, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-0.3582799,53.74422029999999,1600,"Active, not recruiting","Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-2.7995125,54.0423015,1600,"Active, not recruiting","Royal Lancaster Hospital, Lancaster, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Royal Lancaster Hospital, Lancaster, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-2.9641248,53.4093831,1600,"Active, not recruiting","Liverpool University Hospital, Liverpool, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Liverpool University Hospital, Liverpool, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-0.3195181,51.57515009999999,1600,"Active, not recruiting","Northwick Park Hospital, London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Northwick Park Hospital, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-0.165596,51.553237,1600,"Active, not recruiting","Royal Free London NHS Foundation Trust, London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Royal Free London NHS Foundation Trust, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-0.0938548,51.4681404,1600,"Active, not recruiting","King's College Hospital NHS Trust, London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />King's College Hospital NHS Trust, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-0.1340401,51.52455920000001,1600,"Active, not recruiting","University College London, London, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />University College London, London, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-2.2277393,53.4607569,1600,"Active, not recruiting","Manchester University NHS Foundation Trust, Manchester, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Manchester University NHS Foundation Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-2.2277393,53.4607569,1600,"Active, not recruiting","Manchester University NHS Foundation Trust, Manchester, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Manchester University NHS Foundation Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-2.2294865,53.5178824,1600,"Active, not recruiting","Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-4.116408,50.4166994,1600,"Active, not recruiting","Derriford Hospital, Plymouth, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Derriford Hospital, Plymouth, United Kingdom"
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Remdesivir,-1.4923035,53.379171,1600,"Active, not recruiting","Sheffield Teaching Hospitals, Sheffield, United Kingdom","<b>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</b><br /><i>Active, not recruiting, n = 1600</i><br />Sheffield Teaching Hospitals, Sheffield, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-86.8064433,33.5019893,NA,Available,"University of Alabama- Birmingham, Birmingham, Alabama, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Alabama- Birmingham, Birmingham, Alabama, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-112.0575015,33.4646895,NA,Available,"Banner- University Medical Center Phoenix, Phoenix, Arizona, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Banner- University Medical Center Phoenix, Phoenix, Arizona, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-119.7848543,36.742835,NA,Available,"Community Regional Medical Centers (CRMC), Fresno, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Community Regional Medical Centers (CRMC), Fresno, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-117.9272201,33.8943451,NA,Available,"St. Jude Medical Center, Fullerton, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Jude Medical Center, Fullerton, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-117.2255426,32.8851578,NA,Available,"Scripps Memorial Hospital La Jolla, La Jolla, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Scripps Memorial Hospital La Jolla, La Jolla, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-118.1872456,33.8079303,NA,Available,"Long Beach Memorial Medical Center, Long Beach, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Long Beach Memorial Medical Center, Long Beach, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-118.1521448,34.133943,NA,Available,"Huntington Hospital, Pasadena, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Huntington Hospital, Pasadena, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-117.1605004,32.7515454,NA,Available,"Scripps Mercy Hospital, San Diego, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Scripps Mercy Hospital, San Diego, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-122.4347006,37.7683466,NA,Available,"California Pacific Medical Center, San Francisco, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />California Pacific Medical Center, San Francisco, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-122.4578922,37.7627248,NA,Available,"University of California, Medical Center (Parnassus Campus), San Francisco, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of California, Medical Center (Parnassus Campus), San Francisco, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-121.8497581,37.36277,NA,Available,"Regional Medical Center, San Jose, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Regional Medical Center, San Jose, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-122.3003345,37.5308786,NA,Available,"San Mateo Medical Center, San Mateo, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />San Mateo Medical Center, San Mateo, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-122.7013876,38.4436202,NA,Available,"Santa Rosa Memorial Hospital, Santa Rosa, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Santa Rosa Memorial Hospital, Santa Rosa, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-118.8832649,34.207655,NA,Available,"Los Robles Regional Medical Center, Thousand Oaks, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Los Robles Regional Medical Center, Thousand Oaks, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-118.0494059,33.9694666,NA,Available,"PIH Health Whittier Hospital, Whittier, California, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />PIH Health Whittier Hospital, Whittier, California, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-104.8319627,39.6901471,NA,Available,"The Medical Center Of Aurora, Aurora, Colorado, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Medical Center Of Aurora, Aurora, Colorado, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-104.9335815,39.7319823,NA,Available,"Rose Medical Center, Denver, Colorado, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Rose Medical Center, Denver, Colorado, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-104.9805872,39.6538848,NA,Available,"Swedish Medical Center, Englewood, Colorado, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Swedish Medical Center, Englewood, Colorado, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.629904,41.0344748,NA,Available,"Greenwich Hospital, Greenwich, Connecticut, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Greenwich Hospital, Greenwich, Connecticut, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-72.64706389999999,41.5544714,NA,Available,"Middlesex Health, Middletown, Connecticut, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Middlesex Health, Middletown, Connecticut, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-72.7867516,41.6613941,NA,Available,"The Hospital of Central Connecticut, New Britain, Connecticut, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Hospital of Central Connecticut, New Britain, Connecticut, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.5512228,41.0534722,NA,Available,"Stamford Infectious Diseases LLC, Stamford, Connecticut, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Stamford Infectious Diseases LLC, Stamford, Connecticut, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-77.05074119999999,38.901261,NA,Available,"George Washington University Hospital, Washington, District of Columbia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />George Washington University Hospital, Washington, District of Columbia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-80.1457302,25.9702499,NA,Available,"Aventura Hospital and Medical Center, Aventura, Florida, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Aventura Hospital and Medical Center, Aventura, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-80.34546499999999,27.4318538,NA,Available,"Lawnwood Regional Medical Center, Fort Pierce, Florida, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lawnwood Regional Medical Center, Fort Pierce, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-80.1800027,26.0198457,NA,Available,"Memorial Regional Hospital, Hollywood, Florida, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Memorial Regional Hospital, Hollywood, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-81.44514559999999,30.2626481,NA,Available,"Mayo Clinic in Florida, Jacksonville, Florida, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mayo Clinic in Florida, Jacksonville, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-80.14147980000001,25.8130379,NA,Available,"Mount Sinai Medical Center, Miami Beach, Florida, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mount Sinai Medical Center, Miami Beach, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-81.37075089999999,28.5746404,NA,Available,"AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-82.53174,27.3187202,NA,Available,"Sarasota Memorial Hospital, Sarasota, Florida, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Sarasota Memorial Hospital, Sarasota, Florida, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-84.395574,33.8087433,NA,Available,"Piedmont Atlanta Hospital, Atlanta, Georgia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Piedmont Atlanta Hospital, Atlanta, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-84.3729609,33.76290650000001,NA,Available,"Wellstar Atlanta Medical Center, Atlanta, Georgia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wellstar Atlanta Medical Center, Atlanta, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-84.9818414,32.4805568,NA,Available,"Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-84.3820071,33.751785,NA,Available,"Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-84.5081318,33.4527476,NA,Available,"Piedmont Fayette Hospital, Fayetteville, Georgia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Piedmont Fayette Hospital, Fayetteville, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-81.088798,32.030295,NA,Available,"Memorial Health University Medical Center, Savannah, Georgia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Memorial Health University Medical Center, Savannah, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-83.9721278,30.8251693,NA,Available,"John D. Archbold Memorial Hospital, Thomasville, Georgia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />John D. Archbold Memorial Hospital, Thomasville, Georgia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-87.6994788,41.9753719,NA,Available,"Swedish Hospital, Chicago, Illinois, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Swedish Hospital, Chicago, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-95.71695,37.2253156,NA,Available,"Mercy Hospital & Medical Center, Chicago, Illinois, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mercy Hospital & Medical Center, Chicago, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-87.86523799999999,42.2553365,NA,Available,"Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-87.8354513,41.860567,NA,Available,"Loyola University Medical Center, Maywood, Illinois, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Loyola University Medical Center, Maywood, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-88.1562162,41.873256,NA,Available,"Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-86.1442253,39.9821468,NA,Available,"St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-86.1867987,39.77817719999999,NA,Available,"Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-86.0234347,40.0460751,NA,Available,"Riverview Health, Noblesville, Indiana, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Riverview Health, Noblesville, Indiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-91.1075419,30.4040862,NA,Available,"Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-90.0922393,29.92558989999999,NA,Available,"Touro Infirmary, New Orleans, Louisiana, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Touro Infirmary, New Orleans, Louisiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-90.1139717,30.0206297,NA,Available,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ochsner Clinic Foundation, New Orleans, Louisiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-89.7704122,30.2838293,NA,Available,"Slidell Memorial Hospital, Slidell, Louisiana, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Slidell Memorial Hospital, Slidell, Louisiana, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-76.6257057,39.2892017,NA,Available,"University of Maryland, Baltimore, Maryland, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Maryland, Baltimore, Maryland, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-76.612734,39.2930847,NA,Available,"Mercy Medical Center, Baltimore, Maryland, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mercy Medical Center, Baltimore, Maryland, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-76.5963089,38.5593911,NA,Available,"Calvert Health Medical Center, Prince Frederick, Maryland, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Calvert Health Medical Center, Prince Frederick, Maryland, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-76.6117609,39.3882915,NA,Available,"University of Maryland St. Joseph Medical Center, Towson, Maryland, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Maryland St. Joseph Medical Center, Towson, Maryland, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-71.1480227,42.3489047,NA,Available,"Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-71.1044036,42.3748656,NA,Available,"Cambridge Health Alliance, Cambridge, Massachusetts, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Cambridge Health Alliance, Cambridge, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-71.1462713,41.7099524,NA,Available,"Charlton Memorial Hospital, Fall River, Massachusetts, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Charlton Memorial Hospital, Fall River, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-71.1502191,42.709852,NA,Available,"Lawrence General Hospital, Lawrence, Massachusetts, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lawrence General Hospital, Lawrence, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-71.34085,42.647772,NA,Available,"Lowell General Hospital, Lowell, Massachusetts, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lowell General Hospital, Lowell, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-70.9541728,42.1757238,NA,Available,"South Shore Hospital, South Weymouth, Massachusetts, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />South Shore Hospital, South Weymouth, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-71.7920244,42.2730591,NA,Available,"UMass Memorial Medical Center, Worcester, Massachusetts, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />UMass Memorial Medical Center, Worcester, Massachusetts, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-83.65585519999999,42.2650021,NA,Available,"St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-83.49885599999999,42.5925502,NA,Available,"Huron Valley-Sinai Hospital, Commerce, Michigan, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Huron Valley-Sinai Hospital, Commerce, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-83.055094,42.3535427,NA,Available,"Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-83.07581019999999,42.3635022,NA,Available,"Henry Ford Health System, Detroit, Michigan, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Henry Ford Health System, Detroit, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-83.74224199999999,43.011833,NA,Available,"McLaren Health Care Corporation, Flint, Michigan, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />McLaren Health Care Corporation, Flint, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-85.580433,42.2855115,NA,Available,"Bronson Methodist Hospital, Kalamazoo, Michigan, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Bronson Methodist Hospital, Kalamazoo, Michigan, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-90.1736583,32.3299207,NA,Available,"University of Mississippi Medical Center, Jackson, Mississippi, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Mississippi Medical Center, Jackson, Mississippi, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-90.26292889999999,38.6351441,NA,Available,"Washington University School of Medicine, Saint Louis, Missouri, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Washington University School of Medicine, Saint Louis, Missouri, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.11237290000001,40.6681687,NA,Available,"CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.1764487,40.7856535,NA,Available,"Clara Maass Medical Center, Belleville, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Clara Maass Medical Center, Belleville, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-75.1169561,39.9415299,NA,Available,"Cooper University Hospital, Camden, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Cooper University Hospital, Camden, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.3504719,40.5563582,NA,Available,"Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.21450349999999,40.6590205,NA,Available,"Trinitas Regional Medical Center, Elizabeth, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Trinitas Regional Medical Center, Elizabeth, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9687157,40.9042797,NA,Available,"Englewood Health, Englewood, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Englewood Health, Englewood, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.86113,40.5314853,NA,Available,"Hunterdon Medical Center, Flemington, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hunterdon Medical Center, Flemington, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.3109106,40.2386315,NA,Available,"CentraState Medical Center, Freehold, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />CentraState Medical Center, Freehold, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.6716971,40.216006899999996,NA,Available,"Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.0510031,40.7155777,NA,Available,"Jersey City Medical Center, Jersey City, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Jersey City Medical Center, Jersey City, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.0501141,40.7341106,NA,Available,"Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.98543330000001,40.2954704,NA,Available,"Monmouth Medical Center, Long Branch, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Monmouth Medical Center, Long Branch, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.4656519,40.7894006,NA,Available,"Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.0405748,40.2089489,NA,Available,"Jersey Shore University Medical Center, Neptune, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Jersey Shore University Medical Center, Neptune, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.45939299999999,40.5014988,NA,Available,"Saint Peter's University Hospital, New Brunswick, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Peter's University Hospital, New Brunswick, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.17522029999999,40.7443458,NA,Available,"Saint Michael's Medical Center, Newark, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Michael's Medical Center, Newark, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.19019449999999,40.7401785,NA,Available,"University Hospital, Newark, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University Hospital, Newark, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.1316667,40.0769444,NA,Available,"Ocean Medical Center, Oakhurst, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ocean Medical Center, Oakhurst, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.1917012,40.4054853,NA,Available,"Bayshore Medical Center, Red Bank, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Bayshore Medical Center, Red Bank, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.1005112,40.9838774,NA,Available,"The Valley Hospital, Ridgewood, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Valley Hospital, Ridgewood, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.3526072,40.7128985,NA,Available,"Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.010588,40.8827798,NA,Available,"Holy Name Medical Center, Teaneck, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Holy Name Medical Center, Teaneck, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.75206039999999,40.2359639,NA,Available,"Capital Health, Trenton, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Capital Health, Trenton, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.92752569999999,39.8426668,NA,Available,"Virtua Health Voorhees Campus, Voorhees, New Jersey, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Virtua Health Voorhees Campus, Voorhees, New Jersey, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.80371819999999,42.6558325,NA,Available,"St. Peter's Hospital, Albany, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Peter's Hospital, Albany, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9248154,40.7680385,NA,Available,"Mount Sinai Queens, Astoria, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mount Sinai Queens, Astoria, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.2944672,40.6940791,NA,Available,"Good Samaritan Hospital Medical Center, Bay Shore, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Good Samaritan Hospital Medical Center, Bay Shore, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.2415629,40.7258337,NA,Available,"Southside Hospital, Bay Shore, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Southside Hospital, Bay Shore, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9243948,40.816972,NA,Available,"Lincoln Medical Center, Bronx, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lincoln Medical Center, Bronx, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.8913311,40.8529975,NA,Available,"St Barnabus Hospital, Bronx, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St Barnabus Hospital, Bronx, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.84583970000001,40.8492061,NA,Available,"Montefiore Medical Center, Weiler Campus, Bronx, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Montefiore Medical Center, Weiler Campus, Bronx, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.88004099999999,40.8804291,NA,Available,"Montefiore Health System Moses Medical Center, Bronx, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Montefiore Health System Moses Medical Center, Bronx, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9777743,40.691265,NA,Available,"The Brooklyn Hospital Center, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Brooklyn Hospital Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9332436,40.6593818,NA,Available,"Kingsbrook Jewish Medical Center, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kingsbrook Jewish Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.945734,40.6552459,NA,Available,"University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9425116,40.6996948,NA,Available,"Woodhull Medical Center, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Woodhull Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9439771,40.65658699999999,NA,Available,"Kings County Hospital Center, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kings County Hospital Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.0240443,40.60855,NA,Available,"New York Harbor VA Medical Center, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York Harbor VA Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9123577,40.6549713,NA,Available,"Brookdale University Hospital and Medical Center, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Brookdale University Hospital and Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9373439,40.678599,NA,Available,"Interfaith Medical Center, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Interfaith Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.97842399999999,40.6677145,NA,Available,"NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9982409,40.6393024,NA,Available,"Maimonides Medical Center, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Maimonides Medical Center, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.0208955,40.6467233,NA,Available,"NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.94282380000001,40.6187604,NA,Available,"Mount Sinai Brooklyn, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mount Sinai Brooklyn, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9648753,40.5855566,NA,Available,"New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-78.8648375,42.9011764,NA,Available,"Kaleida Health System, Buffalo, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kaleida Health System, Buffalo, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.554059,40.727212,NA,Available,"Nassau University Medical Center, East Meadow, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Nassau University Medical Center, East Meadow, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.8253356,40.7472479,NA,Available,"New York Presbyterian- Queens, Flushing, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York Presbyterian- Queens, Flushing, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.6460742,43.3062687,NA,Available,"Glens Falls Hospital, Glens Falls, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Glens Falls Hospital, Glens Falls, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.8044537,40.7169469,NA,Available,"Queens Hospital Center, Jamaica, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Queens Hospital Center, Jamaica, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9722693,40.746844,NA,Available,"NYU Langone Health, New York, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />NYU Langone Health, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.952559,40.7650229,NA,Available,"Hospital for Special Surgery, New York, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital for Special Surgery, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9444135,40.7848328,NA,Available,"New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.94307839999999,40.8414368,NA,Available,"NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.93950869999999,40.8143104,NA,Available,"New York City Health + Hospitals / Harlem, New York, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York City Health + Hospitals / Harlem, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.004758,40.7099166,NA,Available,"New York Presbyterian Lower Manhattan Hospital, New York, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />New York Presbyterian Lower Manhattan Hospital, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9634264,40.7646529,NA,Available,"Memorial Sloan-Kettering Cancer Center, New York, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Memorial Sloan-Kettering Cancer Center, New York, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.6305987,40.6519366,NA,Available,"Mount Sinai South Nassau, Oceanside, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mount Sinai South Nassau, Oceanside, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.9357942,41.6943079,NA,Available,"Vassar Brothers Medical Center, Poughkeepsie, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Vassar Brothers Medical Center, Poughkeepsie, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-77.5878398,43.1924948,NA,Available,"Rochester General Hospital, Rochester, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Rochester General Hospital, Rochester, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.6702617,40.8046832,NA,Available,"St. Francis Hospital, Roslyn, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Francis Hospital, Roslyn, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.916504,42.8200283,NA,Available,"Ellis Hospital, Schenectady, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ellis Hospital, Schenectady, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.086124,40.5847086,NA,Available,"Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.1162806,40.908827,NA,Available,"Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-73.67267369999999,42.7340076,NA,Available,"Samaritan Hospital, Troy, New York, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Samaritan Hospital, Troy, New York, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-79.0514592,35.9039805,NA,Available,"UNC Hospitals, Chapel Hill, North Carolina, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />UNC Hospitals, Chapel Hill, North Carolina, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-80.8208167,35.2098767,NA,Available,"Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-81.698272,41.4620817,NA,Available,"MetroHealth Medical Center, Cleveland, Ohio, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />MetroHealth Medical Center, Cleveland, Ohio, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-83.0168242,39.9941487,NA,Available,"The Ohio State University College of Medicine, Columbus, Ohio, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Ohio State University College of Medicine, Columbus, Ohio, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-84.1910137,39.6975779,NA,Available,"Kettering Medical Center, Kettering, Ohio, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kettering Medical Center, Kettering, Ohio, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-95.919195,36.072651,NA,Available,"Saint Francis Hospital, Tulsa, Oklahoma, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Francis Hospital, Tulsa, Oklahoma, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-75.39370079999999,40.6089201,NA,Available,"St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-75.2685264,39.92718540000001,NA,Available,"Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-74.9252443,40.2026571,NA,Available,"St Mary Medical Center, Langhorne, Pennsylvania, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St Mary Medical Center, Langhorne, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-75.2001349,39.94798160000001,NA,Available,"Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-75.14235339999999,40.0366347,NA,Available,"Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-80.007677,40.4571516,NA,Available,"Allegheny Health Network, Pittsburgh, Pennsylvania, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Allegheny Health Network, Pittsburgh, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-79.9607843,40.4420639,NA,Available,"UPMC, Pittsburgh, Pennsylvania, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />UPMC, Pittsburgh, Pennsylvania, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-71.4355842,41.8346224,NA,Available,"Roger Williams Medical Center,, Providence, Rhode Island, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Roger Williams Medical Center,, Providence, Rhode Island, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-71.477898,41.705411,NA,Available,"Kent Hospital, Warwick, Rhode Island, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kent Hospital, Warwick, Rhode Island, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-82.4214367,34.8403716,NA,Available,"St. Francis Hospital, Greenville, South Carolina, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Francis Hospital, Greenville, South Carolina, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-81.1135067,34.006705,NA,Available,"Lexington Medical Center, West Columbia, South Carolina, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Lexington Medical Center, West Columbia, South Carolina, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-86.80927989999999,36.1537953,NA,Available,"TriStar Centennial Medical Center, Nashville, Tennessee, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />TriStar Centennial Medical Center, Nashville, Tennessee, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-97.7746416,30.2253622,NA,Available,"St. David's South Austin Medical Center, Austin, Texas, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. David's South Austin Medical Center, Austin, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-96.7614722,32.8796103,NA,Available,"Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-95.5945083,29.7291522,NA,Available,"HCA Houston Healthcare West, Houston, Texas, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />HCA Houston Healthcare West, Houston, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-95.1120193,29.5003947,NA,Available,"University of Texas Medical Branch Galveston, League City, Texas, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Texas Medical Branch Galveston, League City, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-101.8921,33.576903,NA,Available,"Covenant Medical Center, Lubbock, Texas, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Covenant Medical Center, Lubbock, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-97.0944701,32.5683689,NA,Available,"Methodist Mansfield Medical Center, Mansfield, Texas, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Methodist Mansfield Medical Center, Mansfield, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-98.572222,29.5078753,NA,Available,"Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-111.8574151,40.6862543,NA,Available,"Saint Mark's Hospital, Salt Lake City, Utah, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Mark's Hospital, Salt Lake City, Utah, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-77.2281251,38.8573966,NA,Available,"Inova Fairfax Medical Campus, Falls Church, Virginia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Inova Fairfax Medical Campus, Falls Church, Virginia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-77.54013599999999,37.6042575,NA,Available,"Henrico Doctors Hospital, Richmond, Virginia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Henrico Doctors Hospital, Richmond, Virginia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-80.0081915,37.3001642,NA,Available,"Carilion Medical Center, Roanoke, Virginia, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Carilion Medical Center, Roanoke, Virginia, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-122.1868308,47.6208557,NA,Available,"Overlake Hospital Medical Center, Bellevue, Washington, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Overlake Hospital Medical Center, Bellevue, Washington, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-122.3053296,47.6485967,NA,Available,"University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-88.02212,43.0429926,NA,Available,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Medical College of Wisconsin, Milwaukee, Wisconsin, United States"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,151.2207522,-33.8805454,NA,Available,"St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,144.9819197,-37.8456704,NA,Available,"The Alfred Hospital, Melbourne, Victoria, Australia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Alfred Hospital, Melbourne, Victoria, Australia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,144.95617,-37.7989153,NA,Available,"The Royal Melbourne Hospital, Parkville, Victoria, Australia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Royal Melbourne Hospital, Parkville, Victoria, Australia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,11.4041024,47.2692124,NA,Available,"Universitätsklinik für Innere Medizin II, Innsbruck, Austria","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinik für Innere Medizin II, Innsbruck, Austria"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,14.305467,48.303292,NA,Available,"Kepler Universitätsklinikum, Linz, Austria","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kepler Universitätsklinikum, Linz, Austria"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,16.3507732,48.1741674,NA,Available,"Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,4.345909,50.83448680000001,NA,Available,"Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,3.7261488,51.0243757,NA,Available,"Ghent University Hospital, Ghent, Belgium","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ghent University Hospital, Ghent, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,5.3422505,50.91018529999999,NA,Available,"Jessa Ziekenhuis, Hasselt, Belgium","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Jessa Ziekenhuis, Hasselt, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,3.2657973,50.80065440000001,NA,Available,"AZ Groeninge, Kortrijk, Belgium","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />AZ Groeninge, Kortrijk, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,4.6743355,50.8785917,NA,Available,"Universitair Ziekenhuis Leuven, Leuven, Belgium","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitair Ziekenhuis Leuven, Leuven, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,5.567012699999999,50.5725359,NA,Available,"Centre Hospitalier Universitaire de Liège, Liège, Belgium","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire de Liège, Liège, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,4.4390186,50.4307688,NA,Available,"Hôpital Civil Marie Curie, Lodelinsart, Belgium","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hôpital Civil Marie Curie, Lodelinsart, Belgium"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-79.7616899,43.6688351,NA,Available,"William Osler Health System, Brampton, Ontario, Canada","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />William Osler Health System, Brampton, Ontario, Canada"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-75.7214357,45.3925787,NA,Available,"The Ottowa Hospital, Ottawa, Ontario, Canada","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />The Ottowa Hospital, Ottawa, Ontario, Canada"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,33.37701750000001,35.1275993,NA,Available,"Nicosia General Hospital, Nicosia, Cyprus","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Nicosia General Hospital, Nicosia, Cyprus"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,14.421015,50.07339090000001,NA,Available,"Všeobecná fakultní nemocnice v Praze, Prague, Czechia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Všeobecná fakultní nemocnice v Praze, Prague, Czechia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,14.3426023,50.0737696,NA,Available,"Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,14.4640562,50.1153757,NA,Available,"Nemocnice Na Bulovce, Praha 8, Czechia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Nemocnice Na Bulovce, Praha 8, Czechia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,12.5667877,55.6960841,NA,Available,"Rigshospitalet, Copenhagen, Denmark","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Rigshospitalet, Copenhagen, Denmark"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,24.7010389,59.3983667,NA,Available,"Põhja-Eesti Regionaalhaigla, Tallinn, Estonia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Põhja-Eesti Regionaalhaigla, Tallinn, Estonia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,25.2796514,54.6871555,NA,Available,"Vilnius University, Tartu, Estonia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Vilnius University, Tartu, Estonia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,2.425341,48.915811,NA,Available,"Hopital Avicenne, Bobigny, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hopital Avicenne, Bobigny, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-4.528394899999999,48.40151090000001,NA,Available,"Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,3.0914286,45.7592004,NA,Available,"Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,7.337097,48.0755629,NA,Available,"Hôpitaux Civils de Colmar, Colmar, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hôpitaux Civils de Colmar, Colmar, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,2.4563603,48.6205823,NA,Available,"Centre Hospitalier Sud Francilien, Corbeil Essonnes, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Sud Francilien, Corbeil Essonnes, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,2.1706494,48.838653,NA,Available,"Hôpital Raymond Poincaré, Garches, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hôpital Raymond Poincaré, Garches, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,1.9206942,47.8361644,NA,Available,"Centre Hospitalier Régional d'Orléans, Orléans, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Régional d'Orléans, Orléans, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,0.3849052,46.5589271,NA,Available,"Centre Hospitalier Universitaire de Poitiers, Poitiers, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire de Poitiers, Poitiers, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,1.1103553,49.44046489999999,NA,Available,"Hôpital Charles-Nicolle, Rouen, France","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hôpital Charles-Nicolle, Rouen, France"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,7.2299565,51.49178939999999,NA,Available,"Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,13.7765193,51.0544932,NA,Available,"Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,6.989008699999999,51.4364493,NA,Available,"Universitatsklinikum, Essen, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitatsklinikum, Essen, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,7.839487399999999,48.0058642,NA,Available,"Universitätsklinikum Freiburg, Freiburg, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinikum Freiburg, Freiburg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,9.9439393,51.5505609,NA,Available,"Universitätsmedizin Göttingen, Göttingen, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsmedizin Göttingen, Göttingen, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,9.804956899999999,52.3835661,NA,Available,"Medizinische Hochschule Hannover, Hannover, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Medizinische Hochschule Hannover, Hannover, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,8.67066,49.41288,NA,Available,"Universitätsklinikum Heidelberg, Heidelberg, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinikum Heidelberg, Heidelberg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,7.345822600000001,49.3064546,NA,Available,"Universitätsklinikum des Saarlandes, Homburg, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Universitätsklinikum des Saarlandes, Homburg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,12.11875,49.0073861,NA,Available,"Caritas-Krankenhaus St. Josef, Regensburg, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Caritas-Krankenhaus St. Josef, Regensburg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,9.953425,49.7943468,NA,Available,"Klinikum Würzburg Mitte, Würzburg, Germany","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Klinikum Würzburg Mitte, Würzburg, Germany"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,21.7950459,38.2945759,NA,Available,"University General Hospital of Patras Panagia I Voithia, Patra, Greece","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University General Hospital of Patras Panagia I Voithia, Patra, Greece"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,23.0448787,40.6310278,NA,Available,"General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,21.6087213,47.5328052,NA,Available,"Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-21.9273956,64.1384022,NA,Available,"Landspítali, Reykjavik, Iceland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Landspítali, Reykjavik, Iceland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-9.688643200000001,52.2652569,NA,Available,"Kerry University Hospital, Tralee, Ireland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kerry University Hospital, Tralee, Ireland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,35.185261,31.773199,NA,Available,"Shaare Zedek Medical Center, Jerusalem, Israel","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Shaare Zedek Medical Center, Jerusalem, Israel"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,34.8817607,32.0791871,NA,Available,"Hasharon Hospital, Petah Tikva, Israel","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hasharon Hospital, Petah Tikva, Israel"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,34.842852,32.04671,NA,Available,"Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,13.4538759,43.6026491,NA,Available,"Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,16.86185,41.1120624,NA,Available,"Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,11.3628626,44.4917102,NA,Available,"Azienda Ospedaliero Universitaria, Bologna, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero Universitaria, Bologna, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,11.2470215,43.8072546,NA,Available,"Azienda Ospedaliero - Universitaria Careggi, Florence, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero - Universitaria Careggi, Florence, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,8.9696536,44.4079103,NA,Available,"Ospedale Policlinico San Martino, Genova, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ospedale Policlinico San Martino, Genova, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,9.2586677,45.6024956,NA,Available,"Ospedale San Gerardo di Monza, Monza, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Ospedale San Gerardo di Monza, Monza, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,14.2207009,40.8677625,NA,Available,"Azienda Ospedaliera dei Colli, Napoli, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliera dei Colli, Napoli, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,10.395631,43.7217638,NA,Available,"Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,7.674234499999999,45.0413899,NA,Available,"Azienda Ospedaliero Universitaria, Turin, Italy","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Azienda Ospedaliero Universitaria, Turin, Italy"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,5.8611812,51.8235728,NA,Available,"Radboud Universitair Medisch Centrum, Nijmegen, Netherlands","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Radboud Universitair Medisch Centrum, Nijmegen, Netherlands"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,4.2633732,52.0556288,NA,Available,"HagaZiekenhuis, The Hague, Netherlands","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />HagaZiekenhuis, The Hague, Netherlands"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,19.9530916,50.0619877,NA,Available,"Szpital Uniwersytecki w Krakowie, Krakow, Poland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Szpital Uniwersytecki w Krakowie, Krakow, Poland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,16.9307591,52.4062862,NA,Available,"Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,19.0076319,50.1138509,NA,Available,"Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-9.1425133,38.7222155,NA,Available,"Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-8.6195355,41.1472269,NA,Available,"Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-8.6015912,41.1812498,NA,Available,"Centro Hospitalar Universitário De São João, Porto, Portugal","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centro Hospitalar Universitário De São João, Porto, Portugal"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,26.1139908,44.4552889,NA,Available,"Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,27.5843775,47.170543,NA,Available,"Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,21.2554657,48.7078402,NA,Available,"Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,14.5216619,46.0541576,NA,Available,"Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,15.6487876,46.5517074,NA,Available,"Univerzitetni Klinicni Center Maribor, Maribor, Slovenia","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Univerzitetni Klinicni Center Maribor, Maribor, Slovenia"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,2.2378635,41.4810618,NA,Available,"Hospital Universitari Germans Trias i Pujol, Badalona, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitari Germans Trias i Pujol, Badalona, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-3.6724986,40.4185038,NA,Available,"Hospital General Universitario Gregorio Maranon, Madrid, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital General Universitario Gregorio Maranon, Madrid, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-5.8273198,43.3760877,NA,Available,"Hospital Universitario Central de Asturias, Oviedo, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitario Central de Asturias, Oviedo, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,2.6459085,39.6075129,NA,Available,"Hospital Universitario Son Espases, Palma de Mallorca, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitario Son Espases, Palma de Mallorca, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-5.6754372,40.9637872,NA,Available,"Hospital Clinico Universitario de Salamanca, Salamanca, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Clinico Universitario de Salamanca, Salamanca, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-1.9694990000000001,43.292855,NA,Available,"Hospital Universitario Donostia, San Sebastian, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitario Donostia, San Sebastian, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-16.2856164,28.4480627,NA,Available,"Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-4.0348853,39.8715417,NA,Available,"Hospital Virgen De La Salud, Toledo, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Virgen De La Salud, Toledo, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-4.7196729,41.6556947,NA,Available,"Hospital Clinico Universitario de Valladolid, Valladolid, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Clinico Universitario de Valladolid, Valladolid, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-0.9003394,41.6354811,NA,Available,"Hospital Universitario Miguel Servet, Zaragoza, Spain","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Hospital Universitario Miguel Servet, Zaragoza, Spain"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,8.060017499999999,47.3890743,NA,Available,"Kantonsspital Aarau, Aarau, Switzerland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kantonsspital Aarau, Aarau, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,7.5830579,47.5621796,NA,Available,"University Hospital Basel, Basel, Switzerland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University Hospital Basel, Basel, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,7.2445793,47.1468069,NA,Available,"Spitalzentrum Biel, Biel, Switzerland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Spitalzentrum Biel, Biel, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,9.538729199999999,46.8640364,NA,Available,"Kantonsspital Graubünden, Chur, Switzerland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Kantonsspital Graubünden, Chur, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,6.6424293,46.5249174,NA,Available,"Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,8.2974611,47.0576832,NA,Available,"Luzerner Kantonsspital, Luzern, Switzerland","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Luzerner Kantonsspital, Luzern, Switzerland"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-3.1902577,51.50679580000001,NA,Available,"University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-0.0588687,51.5178708,NA,Available,"Barts Health NHS Trust, London, United Kingdom","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Barts Health NHS Trust, London, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-0.1086417,51.49284189999999,NA,Available,"Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-0.1752284,51.42656299999999,NA,Available,"St. George's Hospital, London, United Kingdom","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />St. George's Hospital, London, United Kingdom"
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),Remdesivir,-1.4344979,50.9331825,NA,Available,"Southampton University Hospital, Southampton, United Kingdom","<b>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</b><br /><i>Available, n = NA</i><br />Southampton University Hospital, Southampton, United Kingdom"
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Remdesivir,-111.9544986,33.6583608,40,Not yet recruiting,"Mayo Clinic in Arizona, Phoenix, Arizona, United States","<b>Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19</b><br /><i>Not yet recruiting, n = 40</i><br />Mayo Clinic in Arizona, Phoenix, Arizona, United States"
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Remdesivir,-81.44514559999999,30.2626481,40,Not yet recruiting,"Mayo Clinic in Florida, Jacksonville, Florida, United States","<b>Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19</b><br /><i>Not yet recruiting, n = 40</i><br />Mayo Clinic in Florida, Jacksonville, Florida, United States"
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Remdesivir,-92.46688329999999,44.0226255,40,Not yet recruiting,"Mayo Clinic, Rochester, Minnesota, United States","<b>Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19</b><br /><i>Not yet recruiting, n = 40</i><br />Mayo Clinic, Rochester, Minnesota, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Remdesivir,-117.024154,32.6172649,450,Not yet recruiting,"eStudySite - Chula Vista - PPDS, Chula Vista, California, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />eStudySite - Chula Vista - PPDS, Chula Vista, California, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Remdesivir,-90.1139717,30.0206297,450,Not yet recruiting,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Ochsner Clinic Foundation, New Orleans, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Remdesivir,-93.7608764,32.4807365,450,Not yet recruiting,"Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Remdesivir,-71.0731311,42.3344959,450,Not yet recruiting,"Boston Medical Center, Boston, Massachusetts, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Boston Medical Center, Boston, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Remdesivir,-72.6037013,42.1216158,450,Not yet recruiting,"Baystate Medical Center, Springfield, Massachusetts, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Baystate Medical Center, Springfield, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Remdesivir,-74.17522029999999,40.7443458,450,Not yet recruiting,"St. Michael'S Medical Center, Newark, New Jersey, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />St. Michael'S Medical Center, Newark, New Jersey, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Remdesivir,-111.87937,40.778402,450,Not yet recruiting,"Intermountain LDS Hospital, Salt Lake City, Utah, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Intermountain LDS Hospital, Salt Lake City, Utah, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-86.8039601,33.503198,1032,Recruiting,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-117.225354,32.878285,1032,Recruiting,"University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-118.4466758,34.065656,1032,Recruiting,"University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-117.8891443,33.7885817,1032,Recruiting,"University of California Irvine Medical Center - Infectious Disease, Orange, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California Irvine Medical Center - Infectious Disease, Orange, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-122.1402524,37.405063,1032,Recruiting,"VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-122.1743078,37.4379735,1032,Recruiting,"Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-121.4567734,38.5561515,1032,Recruiting,"University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-117.1455806,32.7263636,1032,Recruiting,"Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-122.4050025,37.7561796,1032,Recruiting,"University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-118.381347,34.0767527,1032,Recruiting,"Cedars Sinai Medical Center, West Hollywood, California, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Cedars Sinai Medical Center, West Hollywood, California, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-104.8298306,39.7428484,1032,Recruiting,"Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-104.9904527,39.7265475,1032,Recruiting,"Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-82.3497282,29.63757429999999,1032,Recruiting,"University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-84.27859699999999,33.790841,1032,Recruiting,"Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-84.3115191,33.8016027,1032,Recruiting,"Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-87.62318499999999,41.8947452,1032,Recruiting,"Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-87.67265599999999,41.8705427,1032,Recruiting,"University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-90.0846281,29.9613085,1032,Recruiting,"Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-76.625715,39.2889604,1032,Recruiting,"University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-76.59273619999999,39.2967385,1032,Recruiting,"Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-77.09384539999999,39.0016164,1032,Recruiting,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Walter Reed National Military Medical Center, Bethesda, Maryland, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-77.1043789,39.0025272,1032,Recruiting,"National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-71.0688334,42.3631542,1032,Recruiting,"Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-71.76325419999999,42.2777464,1032,Recruiting,"University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-93.2311679,44.9711356,1032,Recruiting,"University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-90.231968,38.633482,1032,Recruiting,"Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-95.9759165,41.2548549,1032,Recruiting,"University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-73.8797647,40.8801514,1032,Recruiting,"Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-73.97407369999999,40.7493378,1032,Recruiting,"New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-77.6269403,43.1230503,1032,Recruiting,"University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-78.9430478,36.0076689,1032,Recruiting,"Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-76.674595299999993,40.2643934,1032,Recruiting,"Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-75.19259799999999,39.9476279,1032,Recruiting,"University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-86.80048819999999,36.1424588,1032,Recruiting,"Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-96.8451734,32.8157077,1032,Recruiting,"University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-98.4167342,29.4597886,1032,Recruiting,"Brooke Army Medical Center, Fort Sam Houston, Texas, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Brooke Army Medical Center, Fort Sam Houston, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-94.7786557,29.3113831,1032,Recruiting,"University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-95.39649899999999,29.71052959999999,1032,Recruiting,"Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-98.57535209999999,29.5074654,1032,Recruiting,"University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-78.50048509999999,38.0344004,1032,Recruiting,"University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-76.3046348,36.8437973,1032,Recruiting,"Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-122.1786164,47.715878,1032,Recruiting,"EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-117.4133073,47.6488744,1032,Recruiting,"Providence Sacred Heart Medical Center, Spokane, Washington, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Providence Sacred Heart Medical Center, Spokane, Washington, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-122.55207,47.1097586,1032,Recruiting,"Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,139.716339,35.7016562,1032,Recruiting,"National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,126.9975506,37.57870820000001,1032,Recruiting,"Seoul National University Hospital, Seoul, Korea, Republic of","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Seoul National University Hospital, Seoul, Korea, Republic of"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-99.1553977,19.2891535,1032,Recruiting,"Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,-99.1590142,19.2921803,1032,Recruiting,"Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,103.7834994,1.2922814,1032,Recruiting,"National University Health System - Division of Infectious Diseases, Singapore, Singapore","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />National University Health System - Division of Infectious Diseases, Singapore, Singapore"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,103.8472413,1.3221188,1032,Recruiting,"National Centre for Infectious Diseases (NCID), Singapore, Singapore","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />National Centre for Infectious Diseases (NCID), Singapore, Singapore"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,103.9495701,1.3401915,1032,Recruiting,"Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore"
Adaptive COVID-19 Treatment Trial 2 (ACTT-II),Remdesivir,103.7453915,1.3337448,1032,Recruiting,"Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore","<b>Adaptive COVID-19 Treatment Trial 2 (ACTT-II)</b><br /><i>Recruiting, n = 1032</i><br />Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-113.9839451,51.0789832,2900,Recruiting,"Peter Lougheed Centre, Calgary, Alberta, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Peter Lougheed Centre, Calgary, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-114.1334883,51.0652154,2900,Recruiting,"Foothills Medical Centre, Calgary, Alberta, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Foothills Medical Centre, Calgary, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-114.0974163,50.9903099,2900,Recruiting,"Rockyview General Hospital, Calgary, Alberta, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Rockyview General Hospital, Calgary, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-113.9518929,50.8819537,2900,Recruiting,"South Health Campus, Calgary, Alberta, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />South Health Campus, Calgary, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-113.5232015,53.52076340000001,2900,Recruiting,"University of Alberta Hopsital, Edmonton, Alberta, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />University of Alberta Hopsital, Edmonton, Alberta, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-123.0967667,49.2673536,2900,Recruiting,"Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-123.1280047,49.2806332,2900,Recruiting,"St Paul's Hospital, Vancouver, British Columbia, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />St Paul's Hospital, Vancouver, British Columbia, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-123.3279138,48.4327191,2900,Recruiting,"Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-123.4330644,48.4665044,2900,Recruiting,"Island Health - Victoria General Hospital, Victoria, British Columbia, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Island Health - Victoria General Hospital, Victoria, British Columbia, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-79.7743193,43.2218746,2900,Recruiting,"St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-81.2548309,43.0009154,2900,Recruiting,"St.Joseph's Health Care, London, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />St.Joseph's Health Care, London, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-81.2745418,43.01245309999999,2900,Recruiting,"University Hospital, London, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />University Hospital, London, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-81.22543,42.960029,2900,Recruiting,"Victoria Hospital, London, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Victoria Hospital, London, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-75.6478786,45.4007275,2900,Recruiting,"The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-75.6394863,45.4461659,2900,Recruiting,"Hôpital Montfort, Ottawa, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Hôpital Montfort, Ottawa, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-75.7214357,45.3925787,2900,Recruiting,"The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-75.8076141,45.3349843,2900,Recruiting,"Queensway Carleton Hospital, Ottawa, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Queensway Carleton Hospital, Ottawa, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-79.36274410000001,43.7690968,2900,Recruiting,"North York General Hospital, Toronto, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />North York General Hospital, Toronto, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-79.37565959999999,43.7224812,2900,Recruiting,"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-79.4052302,43.6534793,2900,Recruiting,"Toronto Western Hospital, Toronto, Ontario, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Toronto Western Hospital, Toronto, Ontario, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-73.5574486,45.5112735,2900,Recruiting,"Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-73.60157850000002,45.47326229999999,2900,Recruiting,"McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-71.2107848,46.8152117,2900,Recruiting,"CHU de Québec - Université Laval, Québec, Quebec, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />CHU de Québec - Université Laval, Québec, Quebec, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-71.29770549999999,46.7790343,2900,Recruiting,"Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada"
Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Remdesivir,-71.880256,45.407037,2900,Recruiting,"Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada","<b>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</b><br /><i>Recruiting, n = 2900</i><br />Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-86.8039601,33.503198,800,Recruiting,"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-117.225354,32.878285,800,Recruiting,"University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-118.4466758,34.065656,800,Recruiting,"University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-117.8891443,33.7885817,800,Recruiting,"University of California Irvine Medical Center - Infectious Disease, Orange, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California Irvine Medical Center - Infectious Disease, Orange, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-122.1402524,37.405063,800,Recruiting,"VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-122.1743078,37.4379735,800,Recruiting,"Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-121.4567734,38.5561515,800,Recruiting,"University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-117.1455806,32.7263636,800,Recruiting,"Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-122.4050025,37.7561796,800,Recruiting,"University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-118.381347,34.0767527,800,Recruiting,"Cedars Sinai Medical Center, West Hollywood, California, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Cedars Sinai Medical Center, West Hollywood, California, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-104.9904527,39.7265475,800,Recruiting,"Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-84.27859699999999,33.790841,800,Recruiting,"Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-87.62318499999999,41.8947452,800,Recruiting,"Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-87.67265599999999,41.8705427,800,Recruiting,"University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-90.0846281,29.9613085,800,Recruiting,"Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-76.625715,39.2889604,800,Recruiting,"University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-76.59273619999999,39.2967385,800,Recruiting,"Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-77.09384539999999,39.0016164,800,Recruiting,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Walter Reed National Military Medical Center, Bethesda, Maryland, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-77.1043789,39.0025272,800,Recruiting,"National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-71.0688334,42.3631542,800,Recruiting,"Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-71.76325419999999,42.2777464,800,Recruiting,"University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-93.2311679,44.9711356,800,Recruiting,"University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-90.231968,38.633482,800,Recruiting,"Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-95.9759165,41.2548549,800,Recruiting,"University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-73.8797647,40.8801514,800,Recruiting,"Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-73.97407369999999,40.7493378,800,Recruiting,"New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-77.6269403,43.1230503,800,Recruiting,"University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-78.9430478,36.0076689,800,Recruiting,"Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-76.674595299999993,40.2643934,800,Recruiting,"Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-75.1928899,39.94708019999999,800,Recruiting,"Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-86.80048819999999,36.1424588,800,Recruiting,"Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-98.4167342,29.4597886,800,Recruiting,"Brooke Army Medical Center, Fort Sam Houston, Texas, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Brooke Army Medical Center, Fort Sam Houston, Texas, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-94.7786557,29.3113831,800,Recruiting,"University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-95.39649899999999,29.71052959999999,800,Recruiting,"Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-98.57535209999999,29.5074654,800,Recruiting,"University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-78.50048509999999,38.0344004,800,Recruiting,"University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-76.3046348,36.8437973,800,Recruiting,"Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-122.1786164,47.715878,800,Recruiting,"EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-122.3182835,47.6588389,800,Recruiting,"The University of Washington - Virology Research Clinic, Seattle, Washington, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />The University of Washington - Virology Research Clinic, Seattle, Washington, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-117.4133073,47.6488744,800,Recruiting,"Providence Sacred Heart Medical Center, Spokane, Washington, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Providence Sacred Heart Medical Center, Spokane, Washington, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-122.55207,47.1097586,800,Recruiting,"Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,12.5667877,55.6960841,800,Recruiting,"University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,7.1045497,50.7018469,800,Recruiting,"Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,6.9170435,50.92366209999999,800,Recruiting,"Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,8.6616969,50.0951726,800,Recruiting,"Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,22.9600672,40.62955600000001,800,Recruiting,"AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,23.7786871,37.968196,800,Recruiting,"Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,139.716339,35.7016562,800,Recruiting,"National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,127.1231772,37.3520673,800,Recruiting,"Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,126.9975506,37.57870820000001,800,Recruiting,"Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-99.1553977,19.2891535,800,Recruiting,"Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-99.1590142,19.2921803,800,Recruiting,"Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,103.8472413,1.3221188,800,Recruiting,"National Centre for Infectious Diseases (NCID), Singapore, Singapore","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />National Centre for Infectious Diseases (NCID), Singapore, Singapore"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,2.1523119,41.3894436,800,Recruiting,"Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,2.2378669,41.48111710000001,800,Recruiting,"Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-0.1182958,50.8193472,800,Recruiting,"Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-0.1188545,51.4990946,800,Recruiting,"Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-1.6190553,54.98020570000001,800,Recruiting,"Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-1.5192863,53.80674800000001,800,Recruiting,"St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom"
Adaptive COVID-19 Treatment Trial (ACTT),Remdesivir,-1.2188774,51.764391,800,Recruiting,"John Radcliffe Hospital, Headington, Oxford, United Kingdom","<b>Adaptive COVID-19 Treatment Trial (ACTT)</b><br /><i>Recruiting, n = 800</i><br />John Radcliffe Hospital, Headington, Oxford, United Kingdom"
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,Remdesivir,10.7274539,59.92870980000001,700,Recruiting,"Andreas Barratt-Due, Oslo, Norway","<b>The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients</b><br /><i>Recruiting, n = 700</i><br />Andreas Barratt-Due, Oslo, Norway"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.2558588999999998,49.8728114,3100,Recruiting,"Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,6.2427775,49.0836738,3100,Recruiting,"Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,5.962617799999999,47.22530889999999,3100,Recruiting,"Centre Hospitalier Régional Universitaire de Besançon, Besançon, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Régional Universitaire de Besançon, Besançon, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,-0.6061928,44.829016,3100,Recruiting,"Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.4517989,48.7980441,3100,Recruiting,"APHP - hôpital Henri-Mondor, Créteil, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - hôpital Henri-Mondor, Créteil, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,5.069147099999999,47.3213803,3100,Recruiting,"Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,-61.0380384,14.6339646,3100,Recruiting,"Centre Hospitalier Universitaire de Martinique, Fort De France, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Martinique, Fort De France, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.3522501,48.8105963,3100,Recruiting,"AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,5.7453333,45.1988668,3100,Recruiting,"Centre Hospitalo-Universitaire de Grenoble, La Tronche, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalo-Universitaire de Grenoble, La Tronche, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,3.0347031,50.6108999,3100,Recruiting,"Centre Hospitalier Régional Universitaire de Lille, Lille, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Régional Universitaire de Lille, Lille, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,4.8315594,45.7608649,3100,Recruiting,"Hospices Civils de Lyon, Lyon, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hospices Civils de Lyon, Lyon, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,3.8504425,43.6315886,3100,Recruiting,"Centre Hospitalier Universitaire de Montpellier, Montpellier, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Montpellier, Montpellier, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,7.341206199999999,47.7387331,3100,Recruiting,"Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,6.192022,48.6852009,3100,Recruiting,"Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,-1.5543918,47.2120313,3100,Recruiting,"Centre Hospitalier Universitaire de Nantes, Nantes, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Nantes, Nantes, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,7.2822826,43.7243711,3100,Recruiting,"Centre Hospitalo-Universitaire de Nice, Nice, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalo-Universitaire de Nice, Nice, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.3827263,48.8488116,3100,Recruiting,"APHP - Hôpital Saint Antoine, Paris, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - Hôpital Saint Antoine, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.3650429,48.8370792,3100,Recruiting,"APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.3402667,48.8368937,3100,Recruiting,"APHP - Hôpital Cochin, Paris, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - Hôpital Cochin, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.3103313,48.829771,3100,Recruiting,"Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.2740724,48.8389124,3100,Recruiting,"APHP- Hôpital Européen Georges-Pompidou, Paris, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP- Hôpital Européen Georges-Pompidou, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.3317094,48.8988449,3100,Recruiting,"APHP - Hôpital Bichat Claude Bernard, Paris, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />APHP - Hôpital Bichat Claude Bernard, Paris, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,-1.6950482,48.120059500000004,3100,Recruiting,"Centre Hospitalier Universitaire de Rennes, Rennes, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Rennes, Rennes, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.3711375,48.9335315,3100,Recruiting,"Hopital DELAFONTAINE, Saint-Denis, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hopital DELAFONTAINE, Saint-Denis, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,2.4253137,48.843381,3100,Recruiting,"Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,4.3629634,45.4820275,3100,Recruiting,"Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,7.707166699999999,48.5929237,3100,Recruiting,"Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,1.4369245,43.5995462,3100,Recruiting,"Centre Hospitalier Universitaire de Toulouse, Toulouse, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Toulouse, Toulouse, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,1.4369245,43.5995462,3100,Recruiting,"Centre Hospitalier Universitaire de Toulouse, Toulouse, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Toulouse, Toulouse, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,3.1812134,50.743301,3100,Recruiting,"Centre Hospitalier de Tourcoing, Tourcoing, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier de Tourcoing, Tourcoing, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,0.6696852999999999,47.3872732,3100,Recruiting,"Centre Hospitalier Universitaire de Tours, Tours, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Universitaire de Tours, Tours, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,6.1175557,45.9338394,3100,Recruiting,"Centre Hospitalier Annecy Genevois, Épagny, France","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Annecy Genevois, Épagny, France"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,6.100887999999999,49.618558,3100,Recruiting,"Centre Hospitalier Luxembourg, Luxembourg, Luxembourg","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Centre Hospitalier Luxembourg, Luxembourg, Luxembourg"
Trial of Treatments for COVID-19 in Hospitalized Adults,Remdesivir,6.176546600000001,49.6323792,3100,Recruiting,"Hôpitaux Robert Schuman, Luxembourg, Luxembourg","<b>Trial of Treatments for COVID-19 in Hospitalized Adults</b><br /><i>Recruiting, n = 3100</i><br />Hôpitaux Robert Schuman, Luxembourg, Luxembourg"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Remdesivir,2.523274,48.9545206,400,Recruiting,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France","<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Remdesivir,2.5720537,48.8984523,400,Recruiting,"Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France","<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France"
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",Remdesivir,-118.2075585,34.0575334,144,Recruiting,"Los Angeles County-USC Medical Center, Los Angeles, California, United States","<b>Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19</b><br /><i>Recruiting, n = 144</i><br />Los Angeles County-USC Medical Center, Los Angeles, California, United States"
"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",Remdesivir,-118.2048393,34.0613426,144,Recruiting,"USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States","<b>Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19</b><br /><i>Recruiting, n = 144</i><br />USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States"
Sarilumab for Patients With Moderate COVID-19 Disease,Remdesivir,-71.1099407,42.3272945,120,Recruiting,"VA Boston Healthcare System, Boston, Massachusetts, United States","<b>Sarilumab for Patients With Moderate COVID-19 Disease</b><br /><i>Recruiting, n = 120</i><br />VA Boston Healthcare System, Boston, Massachusetts, United States"
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),Remdesivir,-46.7104346,-23.6477874,500,Not yet recruiting,"Apsen Farmacêutica S.A., São Paulo, Brazil","<b>Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)</b><br /><i>Not yet recruiting, n = 500</i><br />Apsen Farmacêutica S.A., São Paulo, Brazil"
Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse,Remdesivir,2.4517989,48.7980441,6000000,Not yet recruiting,"Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France","<b>Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse</b><br /><i>Not yet recruiting, n = 6000000</i><br />Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,Remdesivir,4.8748526,45.7803551,145,Not yet recruiting,"CNRS, Lyon, France","<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />CNRS, Lyon, France"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,Remdesivir,10.3083481,44.8016341,145,Not yet recruiting,"Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy","<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,Remdesivir,9.3159735,40.3255781,145,Not yet recruiting,"Ospedale San Francesco, Nuoro, Italy","<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />Ospedale San Francesco, Nuoro, Italy"
Convalescent Plasma Therapy in Severe COVID-19 Infection,Remdesivir,90.39467669999999,23.739822,20,Recruiting,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","<b>Convalescent Plasma Therapy in Severe COVID-19 Infection</b><br /><i>Recruiting, n = 20</i><br />Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Remdesivir,-75.28119420000002,2.9321351,1600,Not yet recruiting,"Hospital Universitario de Neiva, Neiva, Huila, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario de Neiva, Neiva, Huila, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Remdesivir,-74.0519893,4.7068994,1600,Not yet recruiting,"Clínica Reina Sofía, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clínica Reina Sofía, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Remdesivir,-74.0345157,4.7413984,1600,Not yet recruiting,"Fundacion Cardio Infantil, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Fundacion Cardio Infantil, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Remdesivir,-74.0640042,4.6282546,1600,Not yet recruiting,"Hospital Universitario San Ignacio, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario San Ignacio, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Remdesivir,-74.1065512,4.6482242,1600,Not yet recruiting,"Clinica Universitaria Colombia, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clinica Universitaria Colombia, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Remdesivir,-74.09571559999999,4.648948499999999,1600,Not yet recruiting,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario Nacional de Colombia, Bogotá, Colombia"
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,Remdesivir,15.9801721,45.8297653,30,Recruiting,"University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia","<b>Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab</b><br /><i>Recruiting, n = 30</i><br />University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia"
Early Short Course Corticosteroids in COVID-19,Remdesivir,-83.0854662,42.3678016,250,Completed,"Henry Ford Hospital, Detroit, Michigan, United States","<b>Early Short Course Corticosteroids in COVID-19</b><br /><i>Completed, n = 250</i><br />Henry Ford Hospital, Detroit, Michigan, United States"
Study of Open Label Losartan in COVID-19,Remdesivir,-94.6113987,39.05634999999999,50,Recruiting,"University of Kansas Medical Center, Kansas City, Kansas, United States","<b>Study of Open Label Losartan in COVID-19</b><br /><i>Recruiting, n = 50</i><br />University of Kansas Medical Center, Kansas City, Kansas, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-117.8265049,33.6845673,120,Recruiting,"Blade Research Site, Irvine, California, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Irvine, California, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-118.4451811,34.068921,120,Recruiting,"Blade Research Site, Los Angeles, California, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Los Angeles, California, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-121.8069487,37.211053,120,Recruiting,"Blade Reseach Site, San Jose, California, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Reseach Site, San Jose, California, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-77.0368707,38.9071923,120,Recruiting,"Blade Research Site, Washington, District of Columbia, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Washington, District of Columbia, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-82.48274289999999,27.9497028,120,Recruiting,"Blade Research Site, Tampa, Florida, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Tampa, Florida, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-89.6145301,40.7097557,120,Recruiting,"Blade Research Site, Peoria, Illinois, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Peoria, Illinois, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-90.1528519,29.9840922,120,Recruiting,"Blade Research Site, Metairie, Louisiana, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Metairie, Louisiana, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-76.6121893,39.2903848,120,Recruiting,"Blade Research Site, Baltimore, Maryland, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Baltimore, Maryland, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-83.0457538,42.331427,120,Recruiting,"Blade Research Site, Detroit, Michigan, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Detroit, Michigan, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-90.19940419999999,38.6270025,120,Recruiting,"Blade Research Site, Saint Louis, Missouri, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Saint Louis, Missouri, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-115.1499011,36.2093572,120,Recruiting,"Blade Research Site, North Las Vegas, Nevada, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, North Las Vegas, Nevada, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-78.8662219,35.923193,120,Recruiting,"Blade Research Site, Durham, North Carolina, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Durham, North Carolina, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-78.87835849999999,35.0526641,120,Recruiting,"Blade Research Site, Fayetteville, North Carolina, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Fayetteville, North Carolina, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-75.15336549999999,39.9383221,120,Recruiting,"Blade Research Site, Philadelphia, Pennsylvania, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Blade Research Site, Philadelphia, Pennsylvania, United States"
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,Remdesivir,-86.80140089999999,36.1425227,120,Recruiting,"Vanderbilt University Medical Center, Nashville, Tennessee, United States","<b>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</b><br /><i>Recruiting, n = 120</i><br />Vanderbilt University Medical Center, Nashville, Tennessee, United States"
Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab,-71.067566,42.3626109,300,Not yet recruiting,"Massachusetts General Hospital, Boston, Massachusetts, United States","<b>Efficacy of Tocilizumab on Patients With COVID-19</b><br /><i>Not yet recruiting, n = 300</i><br />Massachusetts General Hospital, Boston, Massachusetts, United States"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Tocilizumab,-46.6489943,-23.5916438,150,Recruiting,"UNIFESP, São Paulo, Sao Paulo, Brazil","<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />UNIFESP, São Paulo, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Tocilizumab,-46.6436478,-23.5729864,150,Recruiting,"HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil","<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Tocilizumab,-46.6435635,-23.5690595,150,Recruiting,"HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil","<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Tocilizumab,-46.6419505,-23.5664177,150,Recruiting,"Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil","<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Tocilizumab,-46.638029,-23.562,150,Recruiting,"HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil","<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Tocilizumab,-46.7152547,-23.5999606,150,Recruiting,"HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil","<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil"
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Tocilizumab,-46.6537114,-23.5572749,150,Recruiting,"HSL - Hospital Sírio Libanês, Sao Paulo, Brazil","<b>Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers</b><br /><i>Recruiting, n = 150</i><br />HSL - Hospital Sírio Libanês, Sao Paulo, Brazil"
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Tocilizumab,13.5139647,43.6173812,38,"Active, not recruiting","Università Politecnica delle Marche, Ancona, AN, Italy","<b>Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis</b><br /><i>Active, not recruiting, n = 38</i><br />Università Politecnica delle Marche, Ancona, AN, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,8.6116796,44.9072727,400,Recruiting,"Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,8.846696999999999,45.6219651,400,Recruiting,"Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,15.0830304,37.5078772,400,Recruiting,"A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,15.0830304,37.5078772,400,Recruiting,"AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,16.2486644,39.293416,400,Recruiting,"Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,8.931986499999999,45.5952076,400,Recruiting,"ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,10.9421901,44.6363441,400,Recruiting,"Azienda Ospedaliero-Universitaria di Modena, Modena, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Azienda Ospedaliero-Universitaria di Modena, Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,10.9421901,44.6363441,400,Recruiting,"A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,10.9421901,44.6363441,400,Recruiting,"A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,10.9421901,44.6363441,400,Recruiting,"A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,10.9252269,44.647128,400,Recruiting,"Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,14.2096027,40.8706618,400,Recruiting,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,14.222673,40.8624762,400,Recruiting,"National Cancer Institute, Naples, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />National Cancer Institute, Naples, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,14.2096027,40.8706618,400,Recruiting,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,14.2096027,40.8706618,400,Recruiting,"A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,12.9070597,43.9074642,400,Recruiting,"A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,14.0733013,40.849415,400,Recruiting,"Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,12.1902021,44.4100508,400,Recruiting,"Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,15.6594798,38.1130568,400,Recruiting,"Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,12.5889668,44.04740340000001,400,Recruiting,"Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,12.4285757,41.93194039999999,400,Recruiting,"Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,8.8412594,45.8074471,400,Recruiting,"ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,8.8412594,45.8074471,400,Recruiting,"ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,8.8412594,45.8074471,400,Recruiting,"ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,8.8412594,45.8074471,400,Recruiting,"ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,10.9856288,45.4521332,400,Recruiting,"A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy"
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Tocilizumab,10.8394968,45.3474616,400,Recruiting,"Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy","<b>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</b><br /><i>Recruiting, n = 400</i><br />Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy"
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Tocilizumab,7.4247343,46.947267600000004,100,Recruiting,"University Hospital Bern (Inselspital), Bern, Switzerland","<b>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</b><br /><i>Recruiting, n = 100</i><br />University Hospital Bern (Inselspital), Bern, Switzerland"
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Tocilizumab,6.6424293,46.5249174,100,Recruiting,"Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland","<b>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</b><br /><i>Recruiting, n = 100</i><br />Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland"
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Tocilizumab,8.9606,46.0098198,100,Recruiting,"Ospedale Regionale di Lugano (EOC), Viganello, Switzerland","<b>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</b><br /><i>Recruiting, n = 100</i><br />Ospedale Regionale di Lugano (EOC), Viganello, Switzerland"
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Tocilizumab,8.549177499999999,47.3766158,100,Recruiting,"University Hospital Zurich, Zurich, Switzerland","<b>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</b><br /><i>Recruiting, n = 100</i><br />University Hospital Zurich, Zurich, Switzerland"
Tocilizumab Treatment in Patients With COVID-19,Tocilizumab,-99.16038309999999,19.2892389,200,Recruiting,"National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico","<b>Tocilizumab Treatment in Patients With COVID-19</b><br /><i>Recruiting, n = 200</i><br />National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico"
Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab,Tocilizumab,15.9801721,45.8297653,30,Recruiting,"University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia","<b>Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab</b><br /><i>Recruiting, n = 30</i><br />University Hospital for Infectious Diseases ""Dr Fran Mihaljevic"", Zagreb, Croatia"
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19,Tocilizumab,114.309504,30.552113,120,Recruiting,"Tongji Hospital, Wuhan, Hubei, China","<b>Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19</b><br /><i>Recruiting, n = 120</i><br />Tongji Hospital, Wuhan, Hubei, China"
"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Tocilizumab,-87.6042591,41.7887967,50,Recruiting,"University of Chicago Medicine, Chicago, Illinois, United States","<b>Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis</b><br /><i>Recruiting, n = 50</i><br />University of Chicago Medicine, Chicago, Illinois, United States"
"Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia",Tocilizumab,10.1782429,36.8698022,260,Not yet recruiting,"Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia","<b>Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia</b><br /><i>Not yet recruiting, n = 260</i><br />Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia"
A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS,Tocilizumab,-157.8538531,21.3085481,300,Recruiting,"Queen's Medical Center, Honolulu, Hawaii, United States","<b>A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS</b><br /><i>Recruiting, n = 300</i><br />Queen's Medical Center, Honolulu, Hawaii, United States"
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",Tocilizumab,2.174314,41.4136997,276,Recruiting,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","<b>Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19</b><br /><i>Recruiting, n = 276</i><br />Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,Tocilizumab,-73.9634264,40.7646529,40,Recruiting,"Memorial Sloan Kettering Cancer Center, New York, New York, United States","<b>Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection</b><br /><i>Recruiting, n = 40</i><br />Memorial Sloan Kettering Cancer Center, New York, New York, United States"
Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression,Tocilizumab,101.6528322,3.1137086,310,Not yet recruiting,"University Malaya Medical Centre, Kuala Lumpur, Malaysia","<b>Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression</b><br /><i>Not yet recruiting, n = 310</i><br />University Malaya Medical Centre, Kuala Lumpur, Malaysia"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,10.6672675,44.919041,398,Recruiting,"Ospedale di Guastalla, Guastalla, RE, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Ospedale di Guastalla, Guastalla, RE, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,10.4497879,44.7060814,398,Recruiting,"Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,8.6214506,44.9152712,398,Recruiting,"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,10.0523058,45.1300126,398,Recruiting,"ASST Cremona, Cremona, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />ASST Cremona, Cremona, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,7.5366136,44.3853584,398,Recruiting,"Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,11.6963026,44.7998971,398,Recruiting,"Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,11.2476977,43.8072701,398,Recruiting,"Azienda Ospedaliero Universitaria Careggi, Firenze, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliero Universitaria Careggi, Firenze, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,8.9429838,44.414108,398,Recruiting,"Ospedale Evangelico Internazionale di Genova, Genova, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Ospedale Evangelico Internazionale di Genova, Genova, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,8.0119012,43.8802392,398,Recruiting,"Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,9.832067799999999,44.1118233,398,Recruiting,"Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,10.7732402,45.1448334,398,Recruiting,"ASST Mantova - Ospedale Carlo Poma, Mantova, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />ASST Mantova - Ospedale Carlo Poma, Mantova, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,9.145011,45.471875,398,Recruiting,"IRCCS Istituto Auxologico Italiano Milano, Milano, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />IRCCS Istituto Auxologico Italiano Milano, Milano, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,8.621986999999999,45.44200379999999,398,Recruiting,"Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliero-Universitaria ""Maggiore della Carità"" di Novara, Novara, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,11.8846965,45.4127245,398,Recruiting,"Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,10.3083481,44.8016341,398,Recruiting,"Azienda Ospedaliero-Universitaria Parma, Parma, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliero-Universitaria Parma, Parma, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,9.700031899999999,45.0570706,398,Recruiting,"Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,10.4432297,43.7064336,398,Recruiting,"Azienda Ospedaliera Universitaria Pisana, Pisa, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliera Universitaria Pisana, Pisa, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,7.664954099999999,45.0524366,398,Recruiting,"AO Ordine Mauriziano di Torino, Torino, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />AO Ordine Mauriziano di Torino, Torino, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,9.6111994,45.5101004,398,Recruiting,"ASST Bergamo Ovest -Treviglio, Treviglio, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />ASST Bergamo Ovest -Treviglio, Treviglio, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,12.2644188,45.6612591,398,Recruiting,"AULSS 2 Marca Trevigiana, Treviso, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />AULSS 2 Marca Trevigiana, Treviso, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,12.3197938,45.9873685,398,Recruiting,"AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,12.2232083,45.513721,398,Recruiting,"AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />AULSS 3 Serenissima Ospedale ""Dell'Angelo"", Venezia, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,10.9856288,45.4521332,398,Recruiting,"Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy"
Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Tocilizumab,10.9359529,45.5303486,398,Recruiting,"IRCCS Sacro Cuore Don Calabria, Verona, Italy","<b>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</b><br /><i>Recruiting, n = 398</i><br />IRCCS Sacro Cuore Don Calabria, Verona, Italy"
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Tocilizumab,35.1494106,31.7649503,500,Recruiting,"Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel","<b>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</b><br /><i>Recruiting, n = 500</i><br />Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel"
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Tocilizumab,34.5592871,31.6622785,500,Recruiting,"Barzilai Medical Center, Ashkelon, Israel","<b>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</b><br /><i>Recruiting, n = 500</i><br />Barzilai Medical Center, Ashkelon, Israel"
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Tocilizumab,34.7627074,32.0360309,500,Recruiting,"Wolfson Medical Center, H̱olon, Israel","<b>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</b><br /><i>Recruiting, n = 500</i><br />Wolfson Medical Center, H̱olon, Israel"
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Tocilizumab,34.842852,32.04671,500,Recruiting,"Sheba Medical Center, Ramat Gan, Israel","<b>The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation</b><br /><i>Recruiting, n = 500</i><br />Sheba Medical Center, Ramat Gan, Israel"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-112.0575015,33.4646895,379,Recruiting,"Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Banner - University Medical Center Phoenix; In-Patient Pharmacy, Phoenix, Arizona, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-110.9461054,32.2410865,379,Recruiting,"Univ of AZ Coll of Med, Tucson, Arizona, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Univ of AZ Coll of Med, Tucson, Arizona, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-117.083637,32.633558,379,Recruiting,"Scripps Mercy Hospital, Chula Vista, California, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Scripps Mercy Hospital, Chula Vista, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-115.5684684,32.7802257,379,Recruiting,"El Centro Regional Medical Center, El Centro, California, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />El Centro Regional Medical Center, El Centro, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-117.0094774,32.7804422,379,Recruiting,"eStudySite, La Mesa, California, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />eStudySite, La Mesa, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-117.1960044,33.91217779999999,379,Recruiting,"Riverside University Health System-Medical Center, Moreno Valley, California, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Riverside University Health System-Medical Center, Moreno Valley, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-122.2321344,37.79890170000001,379,Recruiting,"Highland Hospital Oakland, Oakland, California, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Highland Hospital Oakland, Oakland, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-122.1428781,37.7127151,379,Recruiting,"San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />San Leandro Hospital; Inpatient Pharmacy, San Leandro, California, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-72.9338698,41.30323,379,Recruiting,"Yale University School Of Medicine, New Haven, Connecticut, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Yale University School Of Medicine, New Haven, Connecticut, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-77.0204624,38.92121710000001,379,Recruiting,"Howard University, Washington, District of Columbia, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Howard University, Washington, District of Columbia, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-80.31765469999999,25.747314,379,Recruiting,"Westchester General Hospital, Miami, Florida, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Westchester General Hospital, Miami, Florida, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-84.9600928,32.5268217,379,Recruiting,"Columbus Regional Research Institute, Columbus, Georgia, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Columbus Regional Research Institute, Columbus, Georgia, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-94.6113987,39.05634999999999,379,Recruiting,"Uni of Kansas Medical Center, Kansas City, Kansas, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Uni of Kansas Medical Center, Kansas City, Kansas, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-90.1436859,29.9631002,379,Recruiting,"Ochsner Clinic, New Orleans, Louisiana, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Ochsner Clinic, New Orleans, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-93.7034604,32.4284824,379,Recruiting,"LSU-Shreveport, Shreveport, Louisiana, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />LSU-Shreveport, Shreveport, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-77.2424097,39.1817574,379,Recruiting,"Holy Cross Germantown Hospital, Germantown, Maryland, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Holy Cross Germantown Hospital, Germantown, Maryland, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-77.0347487,39.0147079,379,Recruiting,"Holy Cross Hospital, Silver Spring, Maryland, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Holy Cross Hospital, Silver Spring, Maryland, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-83.07581019999999,42.3635022,379,Recruiting,"Henry Ford Health System, Detroit, Michigan, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Henry Ford Health System, Detroit, Michigan, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-115.122352,36.114124,379,Recruiting,"Optum Health Care, Las Vegas, Nevada, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Optum Health Care, Las Vegas, Nevada, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-74.1653704,40.9028953,379,Recruiting,"St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />St. Joseph'S Regional Medical Center, Paterson, New Jersey, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-108.2160998,36.7265744,379,Recruiting,"San Juan Oncology Associates, Farmington, New Mexico, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />San Juan Oncology Associates, Farmington, New Mexico, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-73.8913311,40.8529975,379,Recruiting,"St. Barnabas Hospital, Bronx, New York, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />St. Barnabas Hospital, Bronx, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-73.9439771,40.65658699999999,379,Recruiting,"Kings County Hospital Center, Brooklyn, New York, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Kings County Hospital Center, Brooklyn, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-73.9456988,40.65529340000001,379,Recruiting,"SUNY Downstate Medical Center., Brooklyn, New York, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />SUNY Downstate Medical Center., Brooklyn, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-73.8857314,40.74516939999999,379,Recruiting,"Elmhurst Hospital Center, Elmhurst, New York, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Elmhurst Hospital Center, Elmhurst, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-73.8166076,40.7551189,379,Recruiting,"Flushing Hospital, Flushing, New York, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Flushing Hospital, Flushing, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-73.8166244,40.7003783,379,Recruiting,"Jamaica Hospital Medical Center, Jamaica, New York, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Jamaica Hospital Medical Center, Jamaica, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-73.93950869999999,40.8143104,379,Recruiting,"Harlem Hospital, New York, New York, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Harlem Hospital, New York, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-74.9825672,44.6764714,379,Recruiting,"Canton-Potsdam Hospital, Potsdam, New York, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Canton-Potsdam Hospital, Potsdam, New York, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-75.1507582,40.0050435,379,Recruiting,"Temple University Hospital, Philadelphia, Pennsylvania, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Temple University Hospital, Philadelphia, Pennsylvania, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-96.7432104,43.5355194,379,Recruiting,"Sanford Health System, Sioux Falls, South Dakota, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Sanford Health System, Sioux Falls, South Dakota, United States"
A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Tocilizumab,-88.0706558,43.17515179999999,379,Recruiting,"Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States","<b>A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia</b><br /><i>Recruiting, n = 379</i><br />Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-117.2340135,32.8800604,450,"Active, not recruiting","University of California San Diego, La Jolla, California, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University of California San Diego, La Jolla, California, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-117.0094774,32.7804422,450,"Active, not recruiting","eStudySite, La Mesa, California, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />eStudySite, La Mesa, California, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-118.4423562,34.06428289999999,450,"Active, not recruiting","David Geffen School of Medicine UCLA, Los Angeles, California, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />David Geffen School of Medicine UCLA, Los Angeles, California, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-122.169719,37.4274745,450,"Active, not recruiting","Stanford University, Stanford, California, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Stanford University, Stanford, California, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-104.9910801,39.7282404,450,"Active, not recruiting","Denver Health Medical Center, Denver, Colorado, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Denver Health Medical Center, Denver, Colorado, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-80.21199279999999,25.7904064,450,"Active, not recruiting","University of Miami Miller School of Medicine, Miami, Florida, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University of Miami Miller School of Medicine, Miami, Florida, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-87.6674637,41.8747917,450,"Active, not recruiting","Rush University Medical Center, Chicago, Illinois, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Rush University Medical Center, Chicago, Illinois, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-87.5987133,41.7886079,450,"Active, not recruiting","University of Chicago, Chicago, Illinois, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University of Chicago, Chicago, Illinois, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-90.99998509999999,30.442823,450,"Active, not recruiting","Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-72.6037013,42.1216158,450,"Active, not recruiting","Baystate Health System, Springfield, Massachusetts, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Baystate Health System, Springfield, Massachusetts, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-92.46688329999999,44.0226255,450,"Active, not recruiting","Mayo Clinic - PPDS, Rochester, Minnesota, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Mayo Clinic - PPDS, Rochester, Minnesota, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-74.05648819999999,40.8840343,450,"Active, not recruiting","Hackensack University Medical Center, Hackensack, New Jersey, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hackensack University Medical Center, Hackensack, New Jersey, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-74.450131,40.4952121,450,"Active, not recruiting","Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-73.9064045,40.8674032,450,"Active, not recruiting","James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-78.9371331,36.0058487,450,"Active, not recruiting","Duke University Medical Center, Durham, North Carolina, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Duke University Medical Center, Durham, North Carolina, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-81.6211125,41.5025982,450,"Active, not recruiting","Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Cleveland Clinic Foundation; Pulmonary, Allergy & Critical Care Medicine, Cleveland, Ohio, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-75.1560106,39.9478658,450,"Active, not recruiting","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Thomas Jefferson University, Philadelphia, Pennsylvania, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-95.40062239999999,29.707705700000002,450,"Active, not recruiting","Baylor St. Luke's Medical Center, Houston, Texas, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Baylor St. Luke's Medical Center, Houston, Texas, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-95.3933462,29.71064059999999,450,"Active, not recruiting","Ben Taub General Hospital - HCHD, Houston, Texas, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Ben Taub General Hospital - HCHD, Houston, Texas, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-113.5539707,37.0968017,450,"Active, not recruiting","Intermountain Medical Group, Saint George, Utah, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Intermountain Medical Group, Saint George, Utah, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-111.87937,40.778402,450,"Active, not recruiting","Intermountain LDS Hospital, Salt Lake City, Utah, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Intermountain LDS Hospital, Salt Lake City, Utah, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-122.1786164,47.715878,450,"Active, not recruiting","Evergreen Health Infectious Disease, Kirkland, Washington, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Evergreen Health Infectious Disease, Kirkland, Washington, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-122.3795882,47.667469,450,"Active, not recruiting","Swedish Hospital Medical Center, Seattle, Washington, United States","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Swedish Hospital Medical Center, Seattle, Washington, United States"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-79.85409159999999,43.2624646,450,"Active, not recruiting","Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hamilton General Hospital; Pharmacy, Hamilton, Ontario, Canada"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-79.7743193,43.2218746,450,"Active, not recruiting","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-79.38761810000001,43.6598777,450,"Active, not recruiting","University Health Network, Toronto, Ontario, Canada","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University Health Network, Toronto, Ontario, Canada"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-73.5761859,45.513589,450,"Active, not recruiting","Clinical Research Institute of Montreal, Montreal, Quebec, Canada","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Clinical Research Institute of Montreal, Montreal, Quebec, Canada"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,12.5667877,55.6960841,450,"Active, not recruiting","Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,12.470292,55.648779,450,"Active, not recruiting","Hvidovre Hospital, Hvidovre, Denmark","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hvidovre Hospital, Hvidovre, Denmark"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,10.3675736,55.3850091,450,"Active, not recruiting","Odense Universitetshospital, Odense C, Denmark","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Odense Universitetshospital, Odense C, Denmark"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,12.0903485,55.6361646,450,"Active, not recruiting","Sjællands Universitetshospital, Roskilde, Roskilde, Denmark","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Sjællands Universitetshospital, Roskilde, Roskilde, Denmark"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-1.4118805,46.6677714,450,"Active, not recruiting","Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,1.2357132,45.812311,450,"Active, not recruiting","Centre Hospitalier et Universitaire de Limoges, Limoges, France","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Centre Hospitalier et Universitaire de Limoges, Limoges, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,4.8308236,45.7818414,450,"Active, not recruiting","Hôpital de La Croix Rousse, Lyon, France","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hôpital de La Croix Rousse, Lyon, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-1.5545498,47.2107575,450,"Active, not recruiting","Hotel Dieu - Nantes, Nantes, France","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hotel Dieu - Nantes, Nantes, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,2.3650429,48.8370792,450,"Active, not recruiting","Hopital de la Pitie Salpetriere, Paris, France","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hopital de la Pitie Salpetriere, Paris, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,2.3402667,48.8368937,450,"Active, not recruiting","HOPITAL COCHIN university hospital, Paris, France","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />HOPITAL COCHIN university hospital, Paris, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,0.6803135,47.389633,450,"Active, not recruiting","CHRU de Tours, Pharmacie, Tours, France","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />CHRU de Tours, Pharmacie, Tours, France"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,6.788855099999999,51.1987065,450,"Active, not recruiting","Universitatsklinikum Dusseldorf, Dusseldorf, Germany","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Universitatsklinikum Dusseldorf, Dusseldorf, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,9.804956899999999,52.3835661,450,"Active, not recruiting","Medizinische Hochschule Hannover, Hannover, Germany","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Medizinische Hochschule Hannover, Hannover, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,10.1406978,54.3298132,450,"Active, not recruiting","Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,6.917063499999999,50.9234823,450,"Active, not recruiting","Uniklinik Köln, Köln, Germany","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Uniklinik Köln, Köln, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,11.4699801,48.1106346,450,"Active, not recruiting","LMU Klinikum der Universitat Munchen, Munchen, Germany","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />LMU Klinikum der Universitat Munchen, Munchen, Germany"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,14.2207009,40.8677625,450,"Active, not recruiting","Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,12.4564793,41.866501,450,"Active, not recruiting","Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,9.638066,45.686107,450,"Active, not recruiting","ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,9.1230078,45.5192174,450,"Active, not recruiting","ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,9.2586677,45.6024956,450,"Active, not recruiting","Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,9.1488319,45.1962179,450,"Active, not recruiting","Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,4.7628566,51.57417,450,"Active, not recruiting","Amphia Ziekenhuis, Breda, Netherlands","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Amphia Ziekenhuis, Breda, Netherlands"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,5.0789414,52.0249593,450,"Active, not recruiting","St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,4.470303700000001,51.9112533,450,"Active, not recruiting","Erasmus MC, Rotterdam, Netherlands","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Erasmus MC, Rotterdam, Netherlands"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,5.179913099999999,52.0865646,450,"Active, not recruiting","Universitair Medisch Centrum Utrecht, Utrecht, Netherlands","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Universitair Medisch Centrum Utrecht, Utrecht, Netherlands"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,2.1042573,41.3448959,450,"Active, not recruiting","Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,2.142488,41.4283018,450,"Active, not recruiting","Hospital Universitari Vall d'Hebron, Barcelona, Spain","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitari Vall d'Hebron, Barcelona, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,2.1523119,41.3894436,450,"Active, not recruiting","Hospital Clinic de Barcelona, Barcelona, Spain","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Clinic de Barcelona, Barcelona, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-3.6873977,40.4811633,450,"Active, not recruiting","Hospital Universitario La Paz, Madrid, Spain","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitario La Paz, Madrid, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-3.6951156,40.48760430000001,450,"Active, not recruiting","Hospital Universitario Ramon y Cajal, Madrid, Spain","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitario Ramon y Cajal, Madrid, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-3.6724986,40.4185038,450,"Active, not recruiting","Hospital General Universitario Gregorio Maranon, Madrid, Spain","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital General Universitario Gregorio Maranon, Madrid, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-3.6667259,40.4902031,450,"Active, not recruiting","Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-4.321016,55.883619,450,"Active, not recruiting","Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-1.5528918,53.8025196,450,"Active, not recruiting","Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-0.1363551,51.5250834,450,"Active, not recruiting","University College Hospital, London, United Kingdom","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />University College Hospital, London, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-0.1659994,51.55314749999999,450,"Active, not recruiting","Royal Free Hospital, London, United Kingdom","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Royal Free Hospital, London, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-0.2343059,51.516825,450,"Active, not recruiting","St George's Clinical Research Facility, London, United Kingdom","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />St George's Clinical Research Facility, London, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-0.1748772,51.49879970000001,450,"Active, not recruiting","Imperial College London, London, United Kingdom","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Imperial College London, London, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-2.2301193,53.5184925,450,"Active, not recruiting","North Manchester General Hospital, Manchester, United Kingdom","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />North Manchester General Hospital, Manchester, United Kingdom"
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Tocilizumab,-2.3238955,53.487482,450,"Active, not recruiting","Salford Royal Hospital, Salford, United Kingdom","<b>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</b><br /><i>Active, not recruiting, n = 450</i><br />Salford Royal Hospital, Salford, United Kingdom"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-111.9544986,33.6583608,100,Recruiting,"Mayo Clinic - Arizona, Phoenix, Arizona, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Mayo Clinic - Arizona, Phoenix, Arizona, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-110.9461054,32.2410865,100,Recruiting,"Univ of AZ Coll of Med, Tucson, Arizona, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Univ of AZ Coll of Med, Tucson, Arizona, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-117.9272201,33.8943451,100,Recruiting,"St. Jude Medical Center, Fullerton, California, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />St. Jude Medical Center, Fullerton, California, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-118.2075585,34.0575334,100,Recruiting,"LAC + USC Medical Center, Los Angeles, California, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />LAC + USC Medical Center, Los Angeles, California, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-118.2016181,34.0621498,100,Recruiting,"USC Keck Medical Center of USC, Los Angeles, California, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />USC Keck Medical Center of USC, Los Angeles, California, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-73.42227489999999,41.1117461,100,Recruiting,"Norwalk Hospital, Norwalk, Connecticut, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Norwalk Hospital, Norwalk, Connecticut, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-77.0751693,38.911464,100,Recruiting,"Medstar Georgetown University Hospital, Washington, District of Columbia, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Medstar Georgetown University Hospital, Washington, District of Columbia, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-81.6634784,30.347113,100,Recruiting,"University of Florida; Health Science Center, Jacksonville, Florida, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />University of Florida; Health Science Center, Jacksonville, Florida, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-81.44514559999999,30.2626481,100,Recruiting,"Mayo Clinic, Jacksonville, Florida, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Mayo Clinic, Jacksonville, Florida, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-87.73278239999999,41.7217943,100,Recruiting,"Advocate Christ Medical Center, Oak Lawn, Illinois, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Advocate Christ Medical Center, Oak Lawn, Illinois, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-87.8476325,42.0385102,100,Recruiting,"Advocate Lutheran General Hospital, Park Ridge, Illinois, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Advocate Lutheran General Hospital, Park Ridge, Illinois, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-90.18101709999999,30.01050529999999,100,Recruiting,"MedPharmics, Metairie, Louisiana, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />MedPharmics, Metairie, Louisiana, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-76.6257057,39.2892017,100,Recruiting,"University of Maryland, Baltimore, Maryland, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />University of Maryland, Baltimore, Maryland, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-119.7952114,39.52552,100,Recruiting,"Renown Institute for Heart & Vascular Health, Reno, Nevada, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Renown Institute for Heart & Vascular Health, Reno, Nevada, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-74.1653704,40.9028953,100,Recruiting,"St Joseph's Regional Medical Center, Wayne, New Jersey, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />St Joseph's Regional Medical Center, Wayne, New Jersey, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-73.9456988,40.65529340000001,100,Recruiting,"SUNY Downstate Medical Center., Brooklyn, New York, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />SUNY Downstate Medical Center., Brooklyn, New York, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-73.8166244,40.7003783,100,Recruiting,"Jamaica Hospital Medical Center, Jamaica, New York, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Jamaica Hospital Medical Center, Jamaica, New York, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-73.9357942,41.6943079,100,Recruiting,"Vassar Brothers Medical Center, Poughkeepsie, New York, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Vassar Brothers Medical Center, Poughkeepsie, New York, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-80.2791958,36.1355052,100,Recruiting,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-81.6060645,41.5052505,100,Recruiting,"University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-83.54290449999999,41.6686144,100,Recruiting,"Mercy St. Vincent Medical Center, Toledo, Ohio, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Mercy St. Vincent Medical Center, Toledo, Ohio, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-75.5241629,40.5667553,100,Recruiting,"Lehigh Valley Health Network, Allentown, Pennsylvania, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Lehigh Valley Health Network, Allentown, Pennsylvania, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-75.1507582,40.0050435,100,Recruiting,"Temple University Hospital, Philadelphia, Pennsylvania, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Temple University Hospital, Philadelphia, Pennsylvania, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-80.00403179999999,40.4425172,100,Recruiting,"Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Allegheny Health Network (Pittsburg PA), Pittsburgh, Pennsylvania, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-79.9478413,32.7850493,100,Recruiting,"Medical University of South Carolina, Charleston, South Carolina, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Medical University of South Carolina, Charleston, South Carolina, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-95.399568,29.7106626,100,Recruiting,"Houston Methodist Hospital, Houston, Texas, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Houston Methodist Hospital, Houston, Texas, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-95.3889518,29.702086,100,Recruiting,"Michael E. DeBakey VA Medical Center, Houston, Texas, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Michael E. DeBakey VA Medical Center, Houston, Texas, United States"
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Tocilizumab,-95.6309922,29.5891707,100,Recruiting,"Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States","<b>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</b><br /><i>Recruiting, n = 100</i><br />Houston Methodist Sugar Land Hospital, Sugar Land, Texas, United States"
"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Tocilizumab,18.030376,59.3482904,120,Not yet recruiting,"Karolinska University Hospital, Huddinge, Stockholm, Sweden","<b>A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study</b><br /><i>Not yet recruiting, n = 120</i><br />Karolinska University Hospital, Huddinge, Stockholm, Sweden"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Tocilizumab,-117.024154,32.6172649,450,Not yet recruiting,"eStudySite - Chula Vista - PPDS, Chula Vista, California, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />eStudySite - Chula Vista - PPDS, Chula Vista, California, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Tocilizumab,-90.1139717,30.0206297,450,Not yet recruiting,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Ochsner Clinic Foundation, New Orleans, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Tocilizumab,-93.7608764,32.4807365,450,Not yet recruiting,"Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Louisiana State University Health Sciences Center/Ochsner, Shreveport, Louisiana, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Tocilizumab,-71.0731311,42.3344959,450,Not yet recruiting,"Boston Medical Center, Boston, Massachusetts, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Boston Medical Center, Boston, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Tocilizumab,-72.6037013,42.1216158,450,Not yet recruiting,"Baystate Medical Center, Springfield, Massachusetts, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Baystate Medical Center, Springfield, Massachusetts, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Tocilizumab,-74.17522029999999,40.7443458,450,Not yet recruiting,"St. Michael'S Medical Center, Newark, New Jersey, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />St. Michael'S Medical Center, Newark, New Jersey, United States"
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Tocilizumab,-111.87937,40.778402,450,Not yet recruiting,"Intermountain LDS Hospital, Salt Lake City, Utah, United States","<b>A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia</b><br /><i>Not yet recruiting, n = 450</i><br />Intermountain LDS Hospital, Salt Lake City, Utah, United States"
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),Tocilizumab,-84.3194393,33.7928615,180,Recruiting,"Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","<b>Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)</b><br /><i>Recruiting, n = 180</i><br />Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.6653306,38.01659799999999,40,Recruiting,"2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,20.8424173,39.620779,40,Recruiting,"Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,21.7950459,38.2945759,40,Recruiting,"Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.7315473,38.014229,40,Recruiting,"Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.769038,37.992309,40,Recruiting,"Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.7275388,37.9838096,40,Recruiting,"1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.75975,37.9836396,40,Recruiting,"Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.6653306,38.01659799999999,40,Recruiting,"4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.7547649,37.84808719999999,40,Recruiting,"Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.5323004,38.071821,40,Recruiting,"Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,NA,NA,40,Recruiting,"Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,22.4191254,39.63902239999999,40,Recruiting,"Department of Internal Medicine, Larissa University Hospital, Larissa, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Department of Internal Medicine, Larissa University Hospital, Larissa, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,23.7295198,37.93572109999999,40,Recruiting,"Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,22.9586356,40.6372887,40,Recruiting,"Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,22.9444191,40.6400629,40,Recruiting,"Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,22.9617339,40.6116363,40,Recruiting,"Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece"
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Tocilizumab,22.9600672,40.62955600000001,40,Recruiting,"Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece","<b>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</b><br /><i>Recruiting, n = 40</i><br />Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece"
Checkpoint Blockade in COVID-19 Pandemic,Tocilizumab,2.1385079,41.415745,24,Recruiting,"Hospital Quirónsalud Barcelona, Barcelona, Spain","<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Quirónsalud Barcelona, Barcelona, Spain"
Checkpoint Blockade in COVID-19 Pandemic,Tocilizumab,2.174314,41.4136997,24,Recruiting,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
Checkpoint Blockade in COVID-19 Pandemic,Tocilizumab,0.6134759,41.62665,24,Recruiting,"Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain","<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain"
Checkpoint Blockade in COVID-19 Pandemic,Tocilizumab,-3.6951156,40.48760430000001,24,Recruiting,"Hospital Universitario Ramón y Cajal, Madrid, Spain","<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Universitario Ramón y Cajal, Madrid, Spain"
Checkpoint Blockade in COVID-19 Pandemic,Tocilizumab,-3.677653799999999,40.4327229,24,Recruiting,"Hospital Ruber Juan Bravo, Madrid, Spain","<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Ruber Juan Bravo, Madrid, Spain"
Checkpoint Blockade in COVID-19 Pandemic,Tocilizumab,-3.7156662,40.4894832,24,Recruiting,"Hospital Ruber Internacional, Madrid, Spain","<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Ruber Internacional, Madrid, Spain"
Checkpoint Blockade in COVID-19 Pandemic,Tocilizumab,-0.4033429,39.4907502,24,Recruiting,"Hospital Arnau de Vilanova-Lliria, Valencia, Spain","<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Arnau de Vilanova-Lliria, Valencia, Spain"
Checkpoint Blockade in COVID-19 Pandemic,Tocilizumab,-0.393695,39.4524937,24,Recruiting,"Hospital Universitario Doctor Peset, Valencia, Spain","<b>Checkpoint Blockade in COVID-19 Pandemic</b><br /><i>Recruiting, n = 24</i><br />Hospital Universitario Doctor Peset, Valencia, Spain"
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,Tocilizumab,12.5416785,55.7121556,200,Recruiting,"Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark","<b>Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure</b><br /><i>Recruiting, n = 200</i><br />Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark"
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,Tocilizumab,12.326221,55.930868,200,Recruiting,"Hillerød Hospital, Hillerød, Denmark","<b>Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure</b><br /><i>Recruiting, n = 200</i><br />Hillerød Hospital, Hillerød, Denmark"
Randomised Evaluation of COVID-19 Therapy,Tocilizumab,-1.2151574,51.7516232,12000,Recruiting,"Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","<b>Randomised Evaluation of COVID-19 Therapy</b><br /><i>Recruiting, n = 12000</i><br />Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.6172999,55.755826,372,Recruiting,"Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.6172999,55.755826,372,Recruiting,"State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.6172999,55.755826,372,Recruiting,"Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.571717,55.731551,372,Recruiting,"Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.6172999,55.755826,372,Recruiting,"Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.80746269999999,55.7984686,372,Recruiting,"State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.5286696,55.70393490000001,372,Recruiting,"Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.80746269999999,55.7984686,372,Recruiting,"State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,37.6172999,55.755826,372,Recruiting,"АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,30.3609096,59.9310584,372,Recruiting,"Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation"
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Tocilizumab,30.3609096,59.9310584,372,Recruiting,"Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation","<b>Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)</b><br /><i>Recruiting, n = 372</i><br />Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,3.1930172,51.2208468,342,Recruiting,"AZ Sint-Jan Brugge, Brugge, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />AZ Sint-Jan Brugge, Brugge, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,4.345909,50.83448680000001,342,Recruiting,"University Hospital Saint-Pierre, Brussels, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Saint-Pierre, Brussels, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,4.265892,50.813446,342,Recruiting,"Erasmus University Hospital, Brussels, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />Erasmus University Hospital, Brussels, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,4.4520234,50.8529013,342,Recruiting,"University Hospital Saint-Luc, Brussels, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Saint-Luc, Brussels, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,4.4108109,51.15769299999999,342,Recruiting,"University Hospital Antwerp, Edegem, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Antwerp, Edegem, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,5.517904,50.957107,342,Recruiting,"Ziekenhuis Oost-Limurg, Genk, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />Ziekenhuis Oost-Limurg, Genk, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,3.7217947,51.0601558,342,Recruiting,"AZ Sint-Lucas, Gent, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />AZ Sint-Lucas, Gent, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,3.7261488,51.0243757,342,Recruiting,"University Hospital Ghent, Gent, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Ghent, Gent, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,5.3473957,50.9085411,342,Recruiting,"Jessa ZH, Hasselt, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />Jessa ZH, Hasselt, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,4.3086096,50.88780939999999,342,Recruiting,"University Hospital Brussels, Jette, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Brussels, Jette, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,4.2076091,50.477916,342,Recruiting,"CHU Tivoli, La Louvière, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />CHU Tivoli, La Louvière, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,5.577856499999999,50.6521064,342,Recruiting,"CHR de la Citadelle, Liège, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />CHR de la Citadelle, Liège, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,5.5919769,50.6459547,342,Recruiting,"University Hospital Liège, Liège, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />University Hospital Liège, Liège, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,4.5609799,50.667795,342,Recruiting,"Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium"
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Tocilizumab,3.1233251,50.9539257,342,Recruiting,"AZ Delta, Roeselare, Belgium","<b>Treatment of COVID-19 Patients With Anti-interleukin Drugs</b><br /><i>Recruiting, n = 342</i><br />AZ Delta, Roeselare, Belgium"
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,Tocilizumab,37.6172999,55.755826,320,"Active, not recruiting","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation","<b>A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19</b><br /><i>Active, not recruiting, n = 320</i><br />Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Tocilizumab,1.1232334,41.1443624,106,Recruiting,"Hospital Sant Joan de Reus, Reus, Tarragona, Spain","<b>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19</b><br /><i>Recruiting, n = 106</i><br />Hospital Sant Joan de Reus, Reus, Tarragona, Spain"
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Tocilizumab,2.1941912,41.38389069999999,106,Recruiting,"Hospital Del Mar, Barcelona, Spain","<b>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19</b><br /><i>Recruiting, n = 106</i><br />Hospital Del Mar, Barcelona, Spain"
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Tocilizumab,-3.6667259,40.4902031,106,Recruiting,"Hospital Universitario Madrid Sanchinarro, Madrid, Spain","<b>Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19</b><br /><i>Recruiting, n = 106</i><br />Hospital Universitario Madrid Sanchinarro, Madrid, Spain"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Tocilizumab,2.523274,48.9545206,400,Recruiting,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France","<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,Tocilizumab,2.5720537,48.8984523,400,Recruiting,"Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France","<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France"
Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Tocilizumab,51.3435135,35.7091321,55,Recruiting,"Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of","<b>Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients</b><br /><i>Recruiting, n = 55</i><br />Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Tocilizumab,-75.28119420000002,2.9321351,1600,Not yet recruiting,"Hospital Universitario de Neiva, Neiva, Huila, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario de Neiva, Neiva, Huila, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Tocilizumab,-74.0519893,4.7068994,1600,Not yet recruiting,"Clínica Reina Sofía, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clínica Reina Sofía, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Tocilizumab,-74.0345157,4.7413984,1600,Not yet recruiting,"Fundacion Cardio Infantil, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Fundacion Cardio Infantil, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Tocilizumab,-74.0640042,4.6282546,1600,Not yet recruiting,"Hospital Universitario San Ignacio, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario San Ignacio, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Tocilizumab,-74.1065512,4.6482242,1600,Not yet recruiting,"Clinica Universitaria Colombia, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clinica Universitaria Colombia, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Tocilizumab,-74.09571559999999,4.648948499999999,1600,Not yet recruiting,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario Nacional de Colombia, Bogotá, Colombia"
Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Tocilizumab,2.1523119,41.3894436,116,Recruiting,"Hospital Clinic i Provincial de Barcelona, Barcelona, Spain","<b>Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial</b><br /><i>Recruiting, n = 116</i><br />Hospital Clinic i Provincial de Barcelona, Barcelona, Spain"
An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,Tocilizumab,37.6172999,55.755826,320,"Active, not recruiting","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation","<b>An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19</b><br /><i>Active, not recruiting, n = 320</i><br />Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Tocilizumab,-3.6959039,40.4369834,15,Recruiting,"Hospital La Milagrosa, GenesisCare, Madrid, Spain","<b>Ultra Low Doses of Therapy With Radiation Applicated to COVID-19</b><br /><i>Recruiting, n = 15</i><br />Hospital La Milagrosa, GenesisCare, Madrid, Spain"
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Tocilizumab,-0.3867362,39.4607499,15,Recruiting,"Hospital Vithas Valencia Consuelo, Valencia, Spain","<b>Ultra Low Doses of Therapy With Radiation Applicated to COVID-19</b><br /><i>Recruiting, n = 15</i><br />Hospital Vithas Valencia Consuelo, Valencia, Spain"
Study of Open Label Losartan in COVID-19,Tocilizumab,-94.6113987,39.05634999999999,50,Recruiting,"University of Kansas Medical Center, Kansas City, Kansas, United States","<b>Study of Open Label Losartan in COVID-19</b><br /><i>Recruiting, n = 50</i><br />University of Kansas Medical Center, Kansas City, Kansas, United States"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-6.1486211,36.699219,72,Recruiting,"Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-6.1515222,36.5200097,72,Recruiting,"Hospital U. Puerto Real, Puerto Real, Cádiz, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Puerto Real, Puerto Real, Cádiz, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-4.827745,36.5079652,72,Recruiting,"Hospital Costa del Sol, Marbella, Málaga, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Costa del Sol, Marbella, Málaga, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-2.4411846,36.8626932,72,Recruiting,"Hospital U. Torrecárdenas, Almería, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Torrecárdenas, Almería, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-6.278229899999999,36.5089533,72,Recruiting,"Hospital U. Puerta del Mar, Cádiz, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Puerta del Mar, Cádiz, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-3.6099419,37.1885496,72,Recruiting,"Hospital U. Virgen de las Nieves, Granada, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Virgen de las Nieves, Granada, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-3.6050952,37.1466315,72,Recruiting,"Hospital U. San Cecilio, Granada, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. San Cecilio, Granada, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-6.926966999999999,37.2798933,72,Recruiting,"Hospital Juan Ramón Jiménez, Huelva, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Juan Ramón Jiménez, Huelva, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-4.4498416,36.7231736,72,Recruiting,"Hospital Regional U. de Málaga, Málaga, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Regional U. de Málaga, Málaga, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-4.4780498,36.7183379,72,Recruiting,"Hospital U. Virgen de la Victoria, Málaga, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Virgen de la Victoria, Málaga, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-5.986478,37.4065718,72,Recruiting,"Hospital Unversitario Virgen Macarena, Sevilla, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Unversitario Virgen Macarena, Sevilla, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-5.9803696,37.3618418,72,Recruiting,"Hospital Universitario Virgen del Rocío, Sevilla, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital Universitario Virgen del Rocío, Sevilla, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-5.9712578,37.3188416,72,Recruiting,"Hospital U. Nuestra Señora de Valme, Sevilla, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital U. Nuestra Señora de Valme, Sevilla, Spain"
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Tocilizumab,-5.9691386,37.3816501,72,Recruiting,"Hospital San Juan de Dios, Sevilla, Spain","<b>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</b><br /><i>Recruiting, n = 72</i><br />Hospital San Juan de Dios, Sevilla, Spain"
Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,Tocilizumab,-77.1043789,39.0025272,60,Recruiting,"Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation","<b>Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 60</i><br />Federal Research Clinical Center of Federal Medical & Biological Agency, Moscow, Russian Federation"
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Tocilizumab,7.5830579,47.5621796,120,Not yet recruiting,"University Hospital Basel, Division of Internal Medicine, Basel, Switzerland","<b>Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19</b><br /><i>Not yet recruiting, n = 120</i><br />University Hospital Basel, Division of Internal Medicine, Basel, Switzerland"
Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial,HCQ + Azithromycin,5.393300099999999,43.2753932,50,Not yet recruiting,"Hopital Saint Joseph, Marseille, Paca, France","<b>Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial</b><br /><i>Not yet recruiting, n = 50</i><br />Hopital Saint Joseph, Marseille, Paca, France"
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),HCQ + Azithromycin,3.824818499999999,43.6363429,150,Recruiting,"Montpellier University hospital, Montpellier, France","<b>Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)</b><br /><i>Recruiting, n = 150</i><br />Montpellier University hospital, Montpellier, France"
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,HCQ + Azithromycin,-111.8950267,40.6579289,300,Recruiting,"Intermountain Medical Center, Murray, Utah, United States","<b>Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19</b><br /><i>Recruiting, n = 300</i><br />Intermountain Medical Center, Murray, Utah, United States"
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,HCQ + Azithromycin,-111.8421021,40.7649368,300,Recruiting,"University of Utah, Salt Lake City, Utah, United States","<b>Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19</b><br /><i>Recruiting, n = 300</i><br />University of Utah, Salt Lake City, Utah, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,HCQ + Azithromycin,-74.3036941,40.7637521,160,Recruiting,"Saint Barnabas Medical Center, Livingston, New Jersey, United States","<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Saint Barnabas Medical Center, Livingston, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,HCQ + Azithromycin,-73.98543330000001,40.2954704,160,Recruiting,"Monmouth Medical Center, Long Branch, New Jersey, United States","<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Monmouth Medical Center, Long Branch, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,HCQ + Azithromycin,-74.4656519,40.7894006,160,Recruiting,"Morristown Medical Center, Morristown, New Jersey, United States","<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Morristown Medical Center, Morristown, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,HCQ + Azithromycin,-74.450131,40.4952121,160,Recruiting,"Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States","<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,HCQ + Azithromycin,-74.4486555,40.4965117,160,Recruiting,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,HCQ + Azithromycin,-74.1910884,40.7406294,160,Recruiting,"The University Hospital, Newark, New Jersey, United States","<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />The University Hospital, Newark, New Jersey, United States"
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,HCQ + Azithromycin,-74.3536318,40.7127936,160,Recruiting,"Overlook Hospital, Summit, New Jersey, United States","<b>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</b><br /><i>Recruiting, n = 160</i><br />Overlook Hospital, Summit, New Jersey, United States"
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,HCQ + Azithromycin,-111.8950267,40.6579289,1550,Recruiting,"Intermountain Medical Center, Murray, Utah, United States","<b>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19</b><br /><i>Recruiting, n = 1550</i><br />Intermountain Medical Center, Murray, Utah, United States"
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,HCQ + Azithromycin,-111.8421021,40.7649368,1550,Recruiting,"University of Utah, Salt Lake City, Utah, United States","<b>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19</b><br /><i>Recruiting, n = 1550</i><br />University of Utah, Salt Lake City, Utah, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-118.2436849,34.0522342,444,Recruiting,"Novartis Investigative Site, Los Angeles, California, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Los Angeles, California, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-122.3955966,37.7689296,444,Recruiting,"Novartis Investigative Site, San Francisco, California, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, San Francisco, California, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-82.32482619999999,29.6516344,444,Recruiting,"Novartis Investigative Site, Gainesville, Florida, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Gainesville, Florida, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-87.6276182,41.8886599,444,Recruiting,"Novartis Investigative Site, Chicago, Illinois, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Chicago, Illinois, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-91.18714659999999,30.4514677,444,Recruiting,"Novartis Investigative Site, Baton Rouge, Louisiana, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Baton Rouge, Louisiana, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-76.6121893,39.2903848,444,Recruiting,"Novartis Investigative Site, Baltimore, Maryland, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Baltimore, Maryland, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-76.6121893,39.2903848,444,Recruiting,"Novartis Investigative Site, Baltimore, Maryland, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Baltimore, Maryland, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-92.3340724,38.9517053,444,Recruiting,"Novartis Investigative Site, Columbia, Missouri, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Columbia, Missouri, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-79.0558445,35.9131996,444,Recruiting,"Novartis Investigative Site, Chapel Hill, North Carolina, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Chapel Hill, North Carolina, United States"
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,HCQ + Azithromycin,-122.3320708,47.6062095,444,Recruiting,"Novartis Investigative Site, Seattle, Washington, United States","<b>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</b><br /><i>Recruiting, n = 444</i><br />Novartis Investigative Site, Seattle, Washington, United States"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-38.9404,-12.277271,630,"Active, not recruiting","Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-38.4959327,-12.9572223,630,"Active, not recruiting","Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-40.8460076,-14.8626279,630,"Active, not recruiting","HHospital SAMUR, Vitória Da Conquista, BA, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />HHospital SAMUR, Vitória Da Conquista, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-40.8502201,-14.8789474,630,"Active, not recruiting","Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-47.8699039,-15.7651574,630,"Active, not recruiting","Hospital de Brasília, Brasilia, DF, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital de Brasília, Brasilia, DF, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-47.9357361,-15.802223,630,"Active, not recruiting","Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-40.62966410000001,-19.5400456,630,"Active, not recruiting","Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-43.9441692,-19.9803381,630,"Active, not recruiting","Hospital Vila da Serra, Nova Lima, MG, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Vila da Serra, Nova Lima, MG, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-44.2578585,-21.1356146,630,"Active, not recruiting","Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-51.1606506,-23.3266892,630,"Active, not recruiting","Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-43.1876578,-22.913457,630,"Active, not recruiting","Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-51.1562243,-29.1611805,630,"Active, not recruiting","Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-51.2214794,-30.0309242,630,"Active, not recruiting","Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-51.2214794,-30.0309242,630,"Active, not recruiting","Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-49.3643241,-28.6744925,630,"Active, not recruiting","Hospital São José, Criciuma, SC, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital São José, Criciuma, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-48.54495490000001,-27.6011594,630,"Active, not recruiting","Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-48.533927,-27.577689,630,"Active, not recruiting","Hospital Nereu Ramos, Florianópolis, Sc, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Nereu Ramos, Florianópolis, Sc, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-48.845416,-26.289832,630,"Active, not recruiting","Centro Hospitalar Unimed, Joinville, SC, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Centro Hospitalar Unimed, Joinville, SC, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-48.5717864,-20.5545292,630,"Active, not recruiting","Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.4335116,-23.504914,630,"Active, not recruiting","Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.7152547,-23.5999606,630,"Active, not recruiting","Hospital Albert Einstein, São Paulo, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Albert Einstein, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.6419505,-23.5664177,630,"Active, not recruiting","Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.64310810000001,-23.5674333,630,"Active, not recruiting","Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.6698263,-23.5571357,630,"Active, not recruiting","Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.6540085,-23.5969896,630,"Active, not recruiting","Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.643593,-23.5975138,630,"Active, not recruiting","Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.6748267,-23.5849389,630,"Active, not recruiting","Hospital Sírio-Libanês, São Paulo, SP, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital Sírio-Libanês, São Paulo, SP, Brazil"
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),HCQ + Azithromycin,-46.62768819999999,-23.5951605,630,"Active, not recruiting","Hospital SEPACO, São Paulo, S, Brazil","<b>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</b><br /><i>Active, not recruiting, n = 630</i><br />Hospital SEPACO, São Paulo, S, Brazil"
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19,HCQ + Azithromycin,-46.6322189,-23.6181027,200,Suspended,"Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil","<b>Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19</b><br /><i>Suspended, n = 200</i><br />Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",HCQ + Azithromycin,2.4239471,48.91461940000001,27,Suspended,"AP-HP Hôpital Avicenne, Bobigny, France","<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Avicenne, Bobigny, France"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",HCQ + Azithromycin,2.2354935,48.84926069999999,27,Suspended,"AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France","<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",HCQ + Azithromycin,2.3083004,48.9082554,27,Suspended,"AP-HP Hôpital Beaujon, Clichy, France","<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Beaujon, Clichy, France"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",HCQ + Azithromycin,2.3650429,48.8370792,27,Suspended,"AP-HP Hôpital Pitié Salpétrière, Paris, France","<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Pitié Salpétrière, Paris, France"
"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO",HCQ + Azithromycin,2.3827263,48.8488116,27,Suspended,"AP-HP Hôpital Saint Antoine, Paris, France","<b>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</b><br /><i>Suspended, n = 27</i><br />AP-HP Hôpital Saint Antoine, Paris, France"
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19,HCQ + Azithromycin,-46.6322189,-23.6181027,400,Suspended,"Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil","<b>Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19</b><br /><i>Suspended, n = 400</i><br />Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-86.8056842,33.5029685,2000,Recruiting,"Alabama CRS, Birmingham, Alabama, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Alabama CRS, Birmingham, Alabama, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-118.4031397,34.0539099,2000,Recruiting,"UCLA CARE Center CRS, Los Angeles, California, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />UCLA CARE Center CRS, Los Angeles, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-117.1658249,32.7555263,2000,Recruiting,"UCSD Antiviral Research Center CRS, San Diego, California, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />UCSD Antiviral Research Center CRS, San Diego, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-122.4562335,37.7642347,2000,Recruiting,"Ucsf Hiv/Aids Crs, San Francisco, California, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Ucsf Hiv/Aids Crs, San Francisco, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-118.2947364,33.8298404,2000,Recruiting,"Harbor-UCLA CRS, Torrance, California, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Harbor-UCLA CRS, Torrance, California, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-104.8420288,39.7426294,2000,Recruiting,"University of Colorado Hospital CRS, Aurora, Colorado, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Colorado Hospital CRS, Aurora, Colorado, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-77.0315469,38.9104557,2000,Recruiting,"Whitman-Walker Health CRS, Washington, District of Columbia, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Whitman-Walker Health CRS, Washington, District of Columbia, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-87.668852,41.8735131,2000,Recruiting,"Rush University CRS, Chicago, Illinois, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Rush University CRS, Chicago, Illinois, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-71.067566,42.3626109,2000,Recruiting,"Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-74.189656,40.7400804,2000,Recruiting,"New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-73.9932413,40.7441606,2000,Recruiting,"Weill Cornell Chelsea CRS, New York, New York, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Weill Cornell Chelsea CRS, New York, New York, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-73.954897,40.7649151,2000,Recruiting,"Weill Cornell Uptown CRS, New York, New York, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Weill Cornell Uptown CRS, New York, New York, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-77.6260033,43.1305531,2000,Recruiting,"University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-79.0469134,35.9049122,2000,Recruiting,"Chapel Hill CRS, Chapel Hill, North Carolina, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Chapel Hill CRS, Chapel Hill, North Carolina, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-79.7919754,36.0726354,2000,Recruiting,"Greensboro CRS, Greensboro, North Carolina, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Greensboro CRS, Greensboro, North Carolina, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-84.46758489999999,39.1473527,2000,Recruiting,"Cincinnati Clinical Research Site, Cincinnati, Ohio, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Cincinnati Clinical Research Site, Cincinnati, Ohio, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-81.620474,41.504468,2000,Recruiting,"Case Clinical Research Site, Cleveland, Ohio, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Case Clinical Research Site, Cleveland, Ohio, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-83.0306222,40.0068363,2000,Recruiting,"Ohio State University CRS, Columbus, Ohio, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Ohio State University CRS, Columbus, Ohio, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-75.1932137,39.9522188,2000,Recruiting,"Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-79.960835,40.4443533,2000,Recruiting,"University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-86.8026551,36.1447034,2000,Recruiting,"Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-96.8254278,32.744499,2000,Recruiting,"Trinity Health and Wellness Center CRS, Dallas, Texas, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Trinity Health and Wellness Center CRS, Dallas, Texas, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-122.3035199,47.65533509999999,2000,Recruiting,"University of Washington AIDS CRS, Seattle, Washington, United States","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />University of Washington AIDS CRS, Seattle, Washington, United States"
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,HCQ + Azithromycin,-66.0522082,18.3966848,2000,Recruiting,"Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico","<b>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</b><br /><i>Recruiting, n = 2000</i><br />Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico"
Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients,HCQ + Azithromycin,35.8749208,32.0044797,58,Not yet recruiting,"King Hussein Cancer Center, Amman, Jordan","<b>Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients</b><br /><i>Not yet recruiting, n = 58</i><br />King Hussein Cancer Center, Amman, Jordan"
"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",HCQ + Azithromycin,7.7462879,48.5764648,1600,Not yet recruiting,"CHU de Strasbourg, Strasbourg, France","<b>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19</b><br /><i>Not yet recruiting, n = 1600</i><br />CHU de Strasbourg, Strasbourg, France"
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19),HCQ + Azithromycin,-46.7104346,-23.6477874,500,Not yet recruiting,"Apsen Farmacêutica S.A., São Paulo, Brazil","<b>Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)</b><br /><i>Not yet recruiting, n = 500</i><br />Apsen Farmacêutica S.A., São Paulo, Brazil"
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,HCQ + Azithromycin,-73.6702617,40.8046832,750,Recruiting,"St Francis Hospital, Roslyn, New York, United States","<b>Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting</b><br /><i>Recruiting, n = 750</i><br />St Francis Hospital, Roslyn, New York, United States"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,HCQ + Azithromycin,9.9101091,57.03860220000001,226,Recruiting,"Aalborg Sygehus, Aalborg, Denmark","<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Aalborg Sygehus, Aalborg, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,HCQ + Azithromycin,12.5401313,55.7140142,226,Recruiting,"Bispebjerg Hospital, Copenhagen, Denmark","<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Bispebjerg Hospital, Copenhagen, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,HCQ + Azithromycin,12.5467355,55.7388664,226,Recruiting,"Herlev-Gentofte Hospital, Copenhagen, Denmark","<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Herlev-Gentofte Hospital, Copenhagen, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,HCQ + Azithromycin,12.543775,55.71528199999999,226,Recruiting,"Hvidovre Hospital, Copenhagen, Denmark","<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Hvidovre Hospital, Copenhagen, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,HCQ + Azithromycin,12.326221,55.930868,226,Recruiting,"Nordsjællands Hospital, Hillerød, Denmark","<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Nordsjællands Hospital, Hillerød, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,HCQ + Azithromycin,10.3675736,55.3850091,226,Recruiting,"Odense Universitetshospital, Odense, Denmark","<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Odense Universitetshospital, Odense, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,HCQ + Azithromycin,12.0903485,55.6361646,226,Recruiting,"Roskilde Sygehus, Roskilde, Denmark","<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Roskilde Sygehus, Roskilde, Denmark"
Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,HCQ + Azithromycin,11.370371,55.400234,226,Recruiting,"Slagelse Sygehus, Slagelse, Denmark","<b>Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19</b><br /><i>Recruiting, n = 226</i><br />Slagelse Sygehus, Slagelse, Denmark"
Asymptomatic COVID-19 Trial,HCQ + Azithromycin,-74.450131,40.4952121,140,Not yet recruiting,"Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States","<b>Asymptomatic COVID-19 Trial</b><br /><i>Not yet recruiting, n = 140</i><br />Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States"
"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19",HCQ + Azithromycin,2.174314,41.4136997,276,Recruiting,"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","<b>Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19</b><br /><i>Recruiting, n = 276</i><br />Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE),HCQ + Azithromycin,7.7093834,48.5940073,114,Not yet recruiting,"Institut de Cancérologie Strasbourg Europe, Strasbourg, France","<b>Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)</b><br /><i>Not yet recruiting, n = 114</i><br />Institut de Cancérologie Strasbourg Europe, Strasbourg, France"
Azithromycin in Hospitalized COVID-19 Patients,HCQ + Azithromycin,51.3980673,35.8001144,40,Not yet recruiting,"Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","<b>Azithromycin in Hospitalized COVID-19 Patients</b><br /><i>Not yet recruiting, n = 40</i><br />Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of"
Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients,HCQ + Azithromycin,35.8749208,32.0044797,200,Not yet recruiting,"King Hussein Cancer Center, Amman, Jordan","<b>Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients</b><br /><i>Not yet recruiting, n = 200</i><br />King Hussein Cancer Center, Amman, Jordan"
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,HCQ + Azithromycin,-17.4641781,14.6947013,258,Not yet recruiting,"Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal","<b>Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal</b><br /><i>Not yet recruiting, n = 258</i><br />Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal"
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,HCQ + Azithromycin,-17.1636608,14.7268344,258,Not yet recruiting,"Diamniadio Children Hospital, Diamniadio, Senegal","<b>Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal</b><br /><i>Not yet recruiting, n = 258</i><br />Diamniadio Children Hospital, Diamniadio, Senegal"
Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,HCQ + Azithromycin,-17.3996674,14.7753661,258,Not yet recruiting,"Dalal Jamm Hospital, Guédiawaye, Senegal","<b>Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal</b><br /><i>Not yet recruiting, n = 258</i><br />Dalal Jamm Hospital, Guédiawaye, Senegal"
A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,HCQ + Azithromycin,-0.182401,51.4849533,450,Not yet recruiting,"Chelsea and Westminster Hospital, London, United Kingdom","<b>A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe</b><br /><i>Not yet recruiting, n = 450</i><br />Chelsea and Westminster Hospital, London, United Kingdom"
A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,HCQ + Azithromycin,-0.3243212,51.47362889999999,450,Not yet recruiting,"West Middlesex University Hospital, London, United Kingdom","<b>A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe</b><br /><i>Not yet recruiting, n = 450</i><br />West Middlesex University Hospital, London, United Kingdom"
VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),HCQ + Azithromycin,-122.5052644,37.782395,300,"Active, not recruiting","San Francisco VA, San Francisco, California, United States","<b>VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)</b><br /><i>Active, not recruiting, n = 300</i><br />San Francisco VA, San Francisco, California, United States"
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",HCQ + Azithromycin,-111.9264707,33.5871371,80,Recruiting,"Perseverance Research Center, Scottsdale, Arizona, United States","<b>Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19</b><br /><i>Recruiting, n = 80</i><br />Perseverance Research Center, Scottsdale, Arizona, United States"
"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",HCQ + Azithromycin,-90.0715323,29.95106579999999,80,Recruiting,"Covidcraz 19, Llc, New Orleans, Louisiana, United States","<b>Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19</b><br /><i>Recruiting, n = 80</i><br />Covidcraz 19, Llc, New Orleans, Louisiana, United States"
Novel Agents for Treatment of High-risk COVID-19 Positive Patients,HCQ + Azithromycin,-84.5073963,38.0311683,240,Recruiting,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States","<b>Novel Agents for Treatment of High-risk COVID-19 Positive Patients</b><br /><i>Recruiting, n = 240</i><br />University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States"
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,HCQ + Azithromycin,-90.0814661,29.960568,600,Recruiting,"University Medical Center New Orleans, New Orleans, Louisiana, United States","<b>Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease</b><br /><i>Recruiting, n = 600</i><br />University Medical Center New Orleans, New Orleans, Louisiana, United States"
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,HCQ + Azithromycin,14.4378005,50.0755381,240,Recruiting,"František Duška, Praha, Česká Republika, Czechia","<b>Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial</b><br /><i>Recruiting, n = 240</i><br />František Duška, Praha, Česká Republika, Czechia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,HCQ + Azithromycin,-75.28119420000002,2.9321351,1600,Not yet recruiting,"Hospital Universitario de Neiva, Neiva, Huila, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario de Neiva, Neiva, Huila, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,HCQ + Azithromycin,-74.0519893,4.7068994,1600,Not yet recruiting,"Clínica Reina Sofía, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clínica Reina Sofía, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,HCQ + Azithromycin,-74.0345157,4.7413984,1600,Not yet recruiting,"Fundacion Cardio Infantil, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Fundacion Cardio Infantil, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,HCQ + Azithromycin,-74.0640042,4.6282546,1600,Not yet recruiting,"Hospital Universitario San Ignacio, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario San Ignacio, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,HCQ + Azithromycin,-74.1065512,4.6482242,1600,Not yet recruiting,"Clinica Universitaria Colombia, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Clinica Universitaria Colombia, Bogotá, Colombia"
Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,HCQ + Azithromycin,-74.09571559999999,4.648948499999999,1600,Not yet recruiting,"Hospital Universitario Nacional de Colombia, Bogotá, Colombia","<b>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</b><br /><i>Not yet recruiting, n = 1600</i><br />Hospital Universitario Nacional de Colombia, Bogotá, Colombia"
A Study of Quintuple Therapy to Treat COVID-19 Infection,HCQ + Azithromycin,-119.2210602,34.2566277,600,Not yet recruiting,"ProgenaBiome, Ventura, California, United States","<b>A Study of Quintuple Therapy to Treat COVID-19 Infection</b><br /><i>Not yet recruiting, n = 600</i><br />ProgenaBiome, Ventura, California, United States"
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+),HCQ + Azithromycin,10.1782429,36.8698022,400,Not yet recruiting,"Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia","<b>Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)</b><br /><i>Not yet recruiting, n = 400</i><br />Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia"
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,HCQ + Azithromycin,32.8631625,39.9303672,1000,Recruiting,"Hacettepe University, School of Medicine, Ankara, Turkey","<b>Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19</b><br /><i>Recruiting, n = 1000</i><br />Hacettepe University, School of Medicine, Ankara, Turkey"
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,HCQ + Azithromycin,-75.37751639999999,6.1406917,40,Not yet recruiting,"Clinical Somer, Rionegro, Antioquia, Colombia","<b>Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19</b><br /><i>Not yet recruiting, n = 40</i><br />Clinical Somer, Rionegro, Antioquia, Colombia"
Patient Preference Trial for COVID-19 (PPT-COVID),HCQ + Azithromycin,7.4126981,43.7307715,100,Recruiting,"Centre Hospitalier Princesse Grace, Monaco, Monaco","<b>Patient Preference Trial for COVID-19 (PPT-COVID)</b><br /><i>Recruiting, n = 100</i><br />Centre Hospitalier Princesse Grace, Monaco, Monaco"
Bacteriotherapy in the Treatment of COVID-19,HCQ + Azithromycin,12.5144384,41.9037626,70,"Active, not recruiting","Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy","<b>Bacteriotherapy in the Treatment of COVID-19</b><br /><i>Active, not recruiting, n = 70</i><br />Department of Public Heath and Infectious Diseases. University of Rome ""Sapienza"" (Italy), Rome, Italy"
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,HCQ + Azithromycin,37.6172999,55.755826,320,"Active, not recruiting","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation","<b>A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19</b><br /><i>Active, not recruiting, n = 320</i><br />Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation"
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,HCQ + Azithromycin,-79.8457682,43.2401034,1500,Recruiting,"Hamilton Health Sciences, Hamilton, Ontario, Canada","<b>Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial</b><br /><i>Recruiting, n = 1500</i><br />Hamilton Health Sciences, Hamilton, Ontario, Canada"
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,HCQ + Azithromycin,-0.5548297,47.4815099,104,Not yet recruiting,"Chu Angers, Angers, France","<b>Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit</b><br /><i>Not yet recruiting, n = 104</i><br />Chu Angers, Angers, France"
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,HCQ + Azithromycin,-1.4118805,46.6677714,104,Not yet recruiting,"CHD Vendée, La Roche-sur-Yon, France","<b>Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit</b><br /><i>Not yet recruiting, n = 104</i><br />CHD Vendée, La Roche-sur-Yon, France"
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit,HCQ + Azithromycin,0.3849052,46.5589271,104,Not yet recruiting,"CHU Poitiers, Poitiers, France","<b>Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit</b><br /><i>Not yet recruiting, n = 104</i><br />CHU Poitiers, Poitiers, France"
Randomised Evaluation of COVID-19 Therapy,HCQ + Azithromycin,-1.2151574,51.7516232,12000,Recruiting,"Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","<b>Randomised Evaluation of COVID-19 Therapy</b><br /><i>Recruiting, n = 12000</i><br />Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom"
Hydroxychloroquine for COVID-19,HCQ + Azithromycin,9.0576448,48.5216364,220,Recruiting,"Institute for Tropical Medicine, Tübingen, Germany","<b>Hydroxychloroquine for COVID-19</b><br /><i>Recruiting, n = 220</i><br />Institute for Tropical Medicine, Tübingen, Germany"
Treatment for COVID-19 in High-Risk Adult Outpatients,HCQ + Azithromycin,-87.6771887,41.8746646,630,Recruiting,"Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States","<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,HCQ + Azithromycin,-90.12031669999999,29.9407282,630,Recruiting,"Tulane University, New Orleans, Louisiana, United States","<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />Tulane University, New Orleans, Louisiana, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,HCQ + Azithromycin,-71.1053991,42.3504997,630,Recruiting,"Boston University, Boston, Massachusetts, United States","<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />Boston University, Boston, Massachusetts, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,HCQ + Azithromycin,-73.9722693,40.746844,630,Recruiting,"NYU Langone Health, New York, New York, United States","<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />NYU Langone Health, New York, New York, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,HCQ + Azithromycin,-76.1395979,43.0422979,630,Recruiting,"SUNY Upstate Medical University, Syracuse, New York, United States","<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />SUNY Upstate Medical University, Syracuse, New York, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,HCQ + Azithromycin,-122.3035199,47.65533509999999,630,Recruiting,"University of Washington Coordinating Center, Seattle, Washington, United States","<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />University of Washington Coordinating Center, Seattle, Washington, United States"
Treatment for COVID-19 in High-Risk Adult Outpatients,HCQ + Azithromycin,-122.3182835,47.6588389,630,Recruiting,"UW Virology Research Clinic, Seattle, Washington, United States","<b>Treatment for COVID-19 in High-Risk Adult Outpatients</b><br /><i>Recruiting, n = 630</i><br />UW Virology Research Clinic, Seattle, Washington, United States"
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,HCQ + Azithromycin,12.5134687,41.9627606,152,Recruiting,"Francesco Pugliese, Rome, RM, Italy","<b>Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora</b><br /><i>Recruiting, n = 152</i><br />Francesco Pugliese, Rome, RM, Italy"
Efficacy of Ivermectin as Add on Therapy in COVID19 Patients,HCQ + Azithromycin,44.3755185,33.3458996,100,Completed,"General Directorate of Medical City, Bagdad, Baghdad, Iraq","<b>Efficacy of Ivermectin as Add on Therapy in COVID19 Patients</b><br /><i>Completed, n = 100</i><br />General Directorate of Medical City, Bagdad, Baghdad, Iraq"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,HCQ + Azithromycin,2.302302,48.7567574,640,Not yet recruiting,"Hôpital Privé d'Antony, Antony, France","<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Hôpital Privé d'Antony, Antony, France"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,HCQ + Azithromycin,2.4250233,48.9158686,640,Not yet recruiting,"Hôpital Avicenne, Bobigny, France","<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Hôpital Avicenne, Bobigny, France"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,HCQ + Azithromycin,2.4654319,48.79640939999999,640,Not yet recruiting,"Centre Hospitalier Intercommunal de Créteil, Créteil, France","<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Centre Hospitalier Intercommunal de Créteil, Créteil, France"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,HCQ + Azithromycin,2.3103313,48.829771,640,Not yet recruiting,"Groupe Hospitalier Paris Saint-Joseph, Paris, France","<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Groupe Hospitalier Paris Saint-Joseph, Paris, France"
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome,HCQ + Azithromycin,2.3327172,48.822009,640,Not yet recruiting,"Institut Mutualiste Montsouris, Paris, France","<b>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</b><br /><i>Not yet recruiting, n = 640</i><br />Institut Mutualiste Montsouris, Paris, France"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,23.828466,38.0463484,90,Recruiting,"COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,23.6423642,37.9701123,90,Recruiting,"2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,25.873962,40.8457193,90,Recruiting,"2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,23.7653267,37.9833862,90,Recruiting,"1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,23.7275388,37.9838096,90,Recruiting,"2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,23.7793555,37.9950485,90,Recruiting,"3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,20.8424173,39.620779,90,Recruiting,"1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,23.6455378,37.9343508,90,Recruiting,"2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece"
Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,HCQ + Azithromycin,22.9600672,40.62955600000001,90,Recruiting,"1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece","<b>Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early</b><br /><i>Recruiting, n = 90</i><br />1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,HCQ + Azithromycin,2.523274,48.9545206,400,Recruiting,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France","<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France"
Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study,HCQ + Azithromycin,2.5720537,48.8984523,400,Recruiting,"Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France","<b>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</b><br /><i>Recruiting, n = 400</i><br />Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,HCQ + Azithromycin,4.8748526,45.7803551,145,Not yet recruiting,"CNRS, Lyon, France","<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />CNRS, Lyon, France"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,HCQ + Azithromycin,10.3083481,44.8016341,145,Not yet recruiting,"Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy","<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy"
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19,HCQ + Azithromycin,9.3159735,40.3255781,145,Not yet recruiting,"Ospedale San Francesco, Nuoro, Italy","<b>Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19</b><br /><i>Not yet recruiting, n = 145</i><br />Ospedale San Francesco, Nuoro, Italy"
